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Introduction and aim of the study 
Air pollution constitutes a major public health concern because of 
its ubiquity and of its potential short-term and long-term health 
impact. Polluted air contains a complex mixture of particles and 
gas phase pollutants so that individuals are exposed to many air 
pollutants at once. Most pollutants are highly correlated to each 
other, so that an additive or synergic effect cannot be excluded. 
Fine particulate matter (PM2.5, PM1), which is generated by 
combustion, has been suggested to induce mutagenic and toxic 
effects related to particle size and PM concentration and 
composition. The effects of inhaled PM on human health have been 
widely studied in humans as well as in animal models and include 
asthma, cardiovascular issues and premature death due to 
respiratory diseases and probably lung cancer (Pope and Dockery,  
2006; WHO 2000; Rueckerl et al., 2011; Teixeira et al., 2012)  
Recently, the International Agency for Research on Cancer (IARC) 
classified outdoor air pollution as “carcinogenic to humans” 
(Group 1) (Loomis et al., 2013; Hamra et al., 2014). The IARC 
classification was based on the evidence of lung tumours as a 
consequence of lifetime exposure to 10-30 µg/m3 PM2.5. 
It has been also suggested that PM short and long term effects are 
related to particles concentration, chemistry and size (Valavanidis 
et al., 2008). The field of mixture toxicology and the experimental 
analysis of chemical mixtures have undergone a significant 
expansion, which is driven by the need to clarify the effects of 
exposure on human health. Historically, this approach is being 
superseded in favour of investigating the effects of complex 
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mixtures and understanding of the interactions between different 
chemicals. 
Predicting the toxicological risk associated with the exposure to 
environmental samples, such PM extracts, still shows some critical 
issues. The environmental samples are characterized by the 
simultaneous presence of a large number of pollutants, showing 
different mechanisms of action and toxicity profiles.  
The current EU regulation establishes the list of chemicals that 
should be identified and characterized in the airborne PM and set 
the acceptable concentration levels for reference compounds, 
whose toxicological profile has been evaluated in standard tests 
(EU, 2008). The acceptable concentration levels are derived from 
experimental studies. Below these levels, the exposure is 
considered as safe. However, this approach may be inadequate to 
estimate the real risk from several environmental carcinogens co-
present in a complex mixture at low doses.  
Among all of the strategies seeking for the relationships between 
exposure to chemicals and the effects on human health, the 
predictive toxicology approach has the potential to better identify 
biological effects from exposure to environmental mixtures and 
predict the final health outcome, by using in vitro methods 
supported by high throughput approaches and linking them to 
known key steps in disease progression.  
Alternative methods to animal testing are considered as suitable 
tools to support hazard identification and are also of growing 
interest for predicting the toxicological risks. The simultaneous 
presence of a huge number of different chemicals at low 
concentrations could often result in misleading characterization of 
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the hazard associated with complex mixtures, leading to 
underestimation of the risk, since the possible additive or more than 
additive interactions among chemicals could not be properly 
identified (Jarvis, et al., 2014).  
Airborne particulate matter (PM) could be regarded as the 
prototypical example, as it is nearly impossible to identify and 
measure all components in the PM extracts. Moreover, individual 
pollutants in airborne PM samples are often under the acceptable 
concentration level established by the current legislations and near 
or even under the method detection limits. In this context, the 
establishment of in vitro methods able to characterize the toxic 
effects and the carcinogenic potential of mixtures could be relevant 
for hazard and risk assessment.  
Cancer may arise from the exposures to these environmental 
mixtures as the consequence of the interaction among single 
chemicals, each one affecting one (or more) cancer hallmarks. The 
adverse outcome may be reached at doses much lower than those at 
which the effect has been observed in traditional toxicological 
studies. Also, not all components in a complex mixture may be 
equally identified and characterized (Vaccari et al., 2015).  
In recent years, a shift from in vivo costly and time consuming 
animal studies to short term in vitro assays has been proposed to 
assess the hazard of single chemicals or complex mixtures (Collins 
et al., 2008; Kohonen et al., 2014). The UE current regulations on 
the Registration, Evaluation, Authorization and Registration of 
Chemicals (REACH) are prompting the use of alternative test 
methods including in vitro methodologies (EU, 2003, 2006). 
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Among in vitro tests reproducing several stages of the multistep 
process of carcinogenesis, the cell transformation assays (CTAs) 
appear to be the most suitable tools to predict the carcinogenic 
properties of chemicals (Lilienblum et al., 2008; Vasseur and 
Lasne, 2012) and to evaluate the carcinogenic risk associated with 
environmental samples (Colacci et al., 2007; Mascolo et al., 2010; 
Colacci et al., 2014) 
The aim of this thesis is to highlight the toxic and carcinogenic 
potential of airborne particulate matter from different seasons at a 
site that is located in the northern area of the city of Bologna by 
using alternative in vitro tests, such as the cell transformation assay 
with BALB/c 3T3 -clone A31-1-1- and Bhas 42 cells. The purpose 
is also to evaluate the lifetime cancer risks associated with air 
inhalation in different sites, (rural and urban) by using the relative 
potency of compounds belonging to the same chemical class 
(PAHs and nitro-PAHs) and the specific unit of carcinogenic risk.  
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CHAPTER 1  
Alternative tests in vitro 
1.1 Introduction  
Carcinogenesis is a multistage process that can take many years 
before clinical symptoms are manifested. The prediction and the 
assessment of the carcinogenic potential of a new compound is thus 
an essential component of toxicity testing. Historically, the 
evaluation of cancer hazard and potency is assessed using the 
chronic carcinogenicity bioassay in rodents (OECD, 2009) and 
based upon the expectation that the potential to induce tumours in 
rodent can be extrapolated to humans. However, rodent 
carcinogenicity assays are costly, time consuming and use a high 
number of animals and the extrapolation of the results to man is a 
challenging and often imprecise exercise (Mascolo et al., 2010).  
For the last 20 years the scientific community has paid great 
attention to alternative strategies in compliance with common 
moral and ethical values. The European Union began a policy of 
development and use of alternative methods, defined as “systems 
that can be used to replace, reduce or refine the use of animal 
testing in biomedical research, testing and education”.  
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This definition goes back to a text of 1959 (Russell and Burch, 
1959), and is commonly known as the definition of the “3 R: 
replace, reduce, refine”. An alternative to animal testing is defined 
as any technique that:  
-  replace animals with non-sentient alternatives 
(replacement);  
-  reduce to a minimum the number of animals used 
(reduction); 
-  refine experiments which used animals so that they caused 
the minimum pain and distress (refinement). 
Recently, the new European chemical regulation, aiming at the 
Registration, Evaluation and Authorization of Chemicals 
(REACH), which strongly supports the development and use of 
alternative tests to reduce and eventually replace animal bioassays, 
gave added momentum (Reg.EC 1907/2006) and recommends that 
the registration of chemicals is achieved through the least possible 
use of animal testing, to be considered as a last “resort” for 
obtaining information (Lilienblum et al., 2008). 
In vitro studies have considerable advantages for the study of 
carcinogens, such as speed, cost-effectiveness and reproducibility, 
in addition to the possibility of evaluating the dose-response 
relationship. 
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1.2 Cell transformation assay test 
Among in vitro testing methods, cell transformation assay (CTA) 
appears to be one of the most appropriate approaches to predict the 
carcinogenic properties of single chemicals, complex mixtures and 
environmental pollutants (Lilienblum et al., 2008; Mascolo et al, 
2010; Corvi et al, 2012; Vanparys et al, 2012; Vasseur and Lasne, 
2012).  
They are proposed as a second-level screening for carcinogens and 
as a screening test of choice for non-genotoxic carcinogens, which 
are not detected in mutagenicity assays.  
In vitro Cell Transformation Assays (CTAs) have been shown to 
involve a multistage process that closely models some stages of the 
in vivo carcinogenesis. The cellular and molecular changes that are 
involved in the in vitro process of cell transformation are similar to 
those of in vivo carcinogenesis and arise from cellular responses to 
direct and indirect damage to DNA, genes and cellular systems 
(Vanparys et al., 2012; Vasseur and Lasne, 2012).  
Several authors have defined the in vitro cell transformation assay 
as “unique system that offers potential benefit in such screening” 
(Kakanuga, 1985; Montesano et al., 1986; Sakai, 2007).  
These assays measure the induction of malignant features in 
mammalian cells after the treatment with the tested chemicals and 
entail morphological, biochemical and molecular changes in 
behaviour and growth control of cultured cells, such as alteration of 
cell morphology, disorganized pattern of colony growth, and 
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acquisition of anchorage-independent proliferation (Combes et al., 
1999). 
Later on, transformed cells become able to grow in semi-solid agar 
(anchorage-independent growth), produce autocrine growth factors 
and can cause tumours when injected in susceptible animals 
(Combes et al, 1999; Sakai, 2007).  
The transformed cells acquire the ability to divide indefinitely 
(immortalization) which is associated with other alterations like 
aneuploid karyotype and altered genetic stability.  
Chemical carcinogens can be classified into two categories 
according to their ability to interact directly or indirectly with 
DNA: 
genotoxic carcinogens (or their metabolites) are able to initiate 
cells to carcinogenesis via direct interaction with DNA. These 
interactions result in DNA damages and/or structural/numerical 
chromosomal aberrations which can be detected by genotoxicity 
tests. Generally, an evaluation of genotoxic potential focuses on the 
assessment of gene mutations and structural/numerical 
chromosomal aberrations; 
non-genotoxic carcinogens are carcinogenic agents that are, at least 
initially, devoid of direct interaction with DNA. The indirect 
modifications to DNA structures, amount or function may induce 
altered gene expression and/or signal transduction. 
The evaluation of the genotoxic potential of a compound can be 
assessed by a variety of tests that focus on gene mutations and 
chromosomal damage (structural and numerical aberrations). These 
genotoxicity tests are not suitable for the detection of the 
carcinogenic potential of non-genotoxic carcinogens that exhibit 
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indirect modifications to DNA structures/functions and alterations 
in signal transduction pathways and cellular communication.  
It has been shown that the established in vitro cell transformation 
assays are responsive to chemicals acting via genotoxic or non-
genotoxic mechanisms (Sakai, 2007). 
Various types of cell transformation assays have been developed 
for the detection of the carcinogenic potential of chemicals. The 
Syrian hamster embryo cells (SHE) CTA is a primary cell system, 
while C3H 10T1/2, BALB/c 3T3 and Bhas 42, derived by BALB 
A31-1-1, are established cell lines.  
Syrian hamster embryo cells are “normal cells” since they are 
diploid, genetically stable, non tumorigenic cells and are theorized 
to measure the initial stages of transformation, whereas the 
BALB/c 3T3 and C3H 10T1/2 are aneuploid, immortalized cells 
and are hypothesized to measure later stages in the carcinogenic 
process. Bhas 42 cells are supposed to be initiated cells.  
International validation studies of SHE and BALB/c 3T3 CTAs 
were performed by the European Union Reference Laboratory for 
alternatives to animal testing (EURL-ECVAM). Afterwards an 
international validation study of Bhas 42 CTA was performed by 
the Japanese Centre for the Validation of Alternative Methods 
(JaCVAM)  in conjunction with the New Energy and Industrial 
Technology Development Organization (NEDO). This validation 
study ensured the use of standardized Bhas 42 CTA protocol, 
confirmed its transferability between and within laboratories, and 
established its intra and inter laboratory reproducibility.  
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1.2.1 BALB/c 3T3 A31-1-1 Cell Transformation Assay  
BALB/c 3T3 Cell Transformation Assay is one of the three 
available models to investigate the cell transformation in vitro as a 
consequence of the exposure to possible carcinogens. This model 
has been reported to show good predictability of mammalian 
carcinogenicity (IARC/NCI/EPA Working Group 1985, Mascolo et 
al., 2010, Creton et al., 2012). Moreover, a modified protocol of 
the CTA on BALB/c 3T3 has been validated in the EURL-
ECVAM (Sasaki et al., 2012 a,b).  
BALB/c 3T3 cells are immortalized embryonic mouse fibroblast. 
These aneuploid, contact-inhibited cells are able to grow as a 
monolayer culture until confluent. The chemical transformation of 
3T3 cells results in the induction of morphologically aberrant foci, 
shaped with cells that do not stop proliferating at confluence but 
grow over contact-inhibited normal cells. Only foci that show 
basophilic dense multilayering of cells, random orientation at the 
focus edge, invasion into the surrounding contact-inhibited 
monolayer and domination of spindle shaped cells are recognized 
as positive transformed foci (Kakanuga, 1985; Sakai, 2007) 
1.2.2 Bhas 42 Cell Transformation Assay  
The Bhas 42 cell line was established by the transfection with a 
plasmid pBR322 containing vHa-ras oncogene into the BALB/c 
3T3 A31-1-1 cell line (Sasaki, et al., 1988; Sasaki et al, 2010). 
Similar to the parental BALB/c 3T3 cell line, untransformed Bhas 
42 cells grow to confluence forming a contact-inhibited monolayer 
and lack tumorigenicity upon transplantation in vivo. After 
exposure to carcinogenic stimuli, Bhas 42 cells can become 
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morphologically altered and form independent aberrant colonies, 
referred to as transformed foci, capable of invading the surrounding 
non-transformed contact-inhibited monolayer.  
The Bhas 42 cell transformation assay has recently been evaluated 
by comparing it with the BALB/c 3T3 transformation assay 
(Muramatsu, et al., 2009), by analyzing the performance of 
detection of chemicals carcinogenicity (Ohmori, et al., 2004; Sakai, 
et al.,2010) in interlaboratory collaborative studies (Ohmori, 2005; 
Tanaka, et al., 2009), and in an international validation study 
(Sakai, et al., 2011).  
These studies show that the Bhas 42 cell transformation assay is 
reproducible and reliable and has the following advantages, when 
compared to the BALB/c 3T3 cell transformation assay: 
 it is a simple assay: treatment with a tumour initiator can be 
omitted to detect tumour promotors 
 it is a short – term assay: the culture period is shortened from 4 
to 6 weeks to 2.5 to 3 weeks; 
 it is a sensitive assay: specificity is high 
 it is economical assay: six wells of 6-wells plates are required 
for each dose, instead of 8 to 12 60-mm dishes (Ohmori, et al., 
2009). 
Several comprehensive studies were performed to assess the 
relevance and predictive reliability of the Bhas 42 CTA. These 
included:  
 extensive analysis of 98 chemicals (Sakai et al., 2010),  
 a multi-laboratory collaborative study (Ohmori et al., 2005),  
 a prevalidation study (Tanaka et al., 2009), 
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 two international validation studies (Sakai, et al., 2011) 
The results of all of these studies confirmed the applicability, 
transferability, reproducibility and reliability of the Bhas 42 CTA 
protocol and the assay was found to be sufficiently sensitive to 
predict both initiating activity and promoting activity of 
carcinogens.  
13 
 
 
1.3 Application of the CTAs in various industry 
sectors 
1.3.1 Pharmaceutical industry 
For carcinogenicity testing, the rodent bioassay is still a required 
method within the pharmaceutical field. Long-term rodent 
carcinogenicity studies are associated with high cost and time 
making them unsuitable for carcinogenic screening (Vanparys et 
al., 2012). For these reasons, the cell transformation assays (CTAs) 
have been used by some in pharmaceutical industry. The CTAs are 
mentioned in the FDA guidance as a recommended approached for 
the integration of genetic toxicology study results (FDA, 2006; 
Vanparys et al., 2012). Cell transformation assays could be 
considered in the pharmaceutical industry as another tool for 
screening for potential carcinogens during early phases of drug 
development. They can also be used to show similarities or 
differences through compounds of the same family.  
1.3.2 Chemical industry  
The development of the Registration, Evaluation, Authorization 
and Restriction of Chemicals (REACH) policy requires the 
registration of thousands of individual substances (EU, 2006).  
CTAs are used in the chemical industry to investigate the 
carcinogenic potential of genotoxic compounds or to determine 
whether a non genotoxic chemical is a potential non genotoxic 
carcinogen (Vanparys et al., 2012).  
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1.3.3 Cosmetic industry  
Due to the 7th Amendment to the EU Cosmetics Directive 
76/768/EEC testing ban that was promulgated March 2009  (EU, 
2003) it is not possible to perform acute in vivo genotoxicity testing 
for cosmetic ingredients. However, until 2013, in vivo genotoxicity 
testing may be still conducted if integrated in repeated dose toxicity 
studies (Pfuhler et al., 2009). In the absence of the possibility of 
performing in vivo testing after 2013, CTAs provide a useful 
approach to obtain additional hazard information with the data 
obtained in the conventional in vitro genotoxicity test batteries 
(Adler et al., 2011). 
1.3.4 Food industry  
The European Food Safety Authority (EFSA) published in 2011 a 
scientific opinion on genotoxicity testing strategies applicable to 
food and feed safety assessment (EFSA, 2011). The EFSA opinion 
also suggests that CTAs can be useful for investigation of 
substances with structural alerts for carcinogenicity and to 
demonstrate similarities or differences across chemical categories 
of food ingredients (Vanparys et al., 2012).  
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CHAPTER 2  
2.1 Risk assessment  
Risk assessment is the process that scientists and government 
officials use to estimate the increased risk of health problems in 
people who are exposed to different amounts of toxic substances. 
Risk assessment is a four-step process, including hazard 
identification, dose-response modelling, exposure assessment and 
risk characterization. (Figure 2.1) 
Figure 2.1: The four-step process in the risk assessment 
source http://www3.epa.gov/airtoxics/3_90_024.html 
 
The dose-response modelling and the exposure assessment are 
combined to quantify the risk associated with current and 
anticipated exposures. The risk characterization step presents both 
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the qualitative likelihood that the hazard will occur and the 
quantitative estimates of risk.  
The hazard identification is the description of the toxic potential of 
the analyzed agent. It is based on the evaluation of all available 
data (e.g., epidemiology, animal bioassay studies, and in vivo and 
in vitro studies) to characterize the strength of evidence indicating 
potential health effects that might occur in exposed human 
populations.  
The first step in cancer risk assessment is to determine the 
carcinogenicity to humans of a specific exposure. The degree of 
uncertainty in the classification process depends on the availability 
of adequate and acceptable data. The best type of evidence comes 
from human studies. 
The international institutions which are mainly involved in 
identifying and classifying the risk of carcinogenicity of agents and 
exposures are: 
- the International Agency for Research on Cancer (IARC) which 
publishes the Monographs on the Evaluation of Carcinogenic Risks 
to Humans,  
- the US National Toxicology Program (NTP) which publishes 
every two months, the Report on Carcinogens,  
- the U.S. Environmental Protection Agency (U.S. EPA) that 
develops assessment of carcinogenic risk. 
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The IARC categorizes agents, mixtures and exposures into five 
categories (IARC, 2010b):  
Group 1: “the agent (mixture) is carcinogenic to humans. The 
exposure circumstance entails exposures that are carcinogenic to 
humans”. This category is used when there is sufficient evidence of 
carcinogenicity in humans. Exceptionally, an agent (mixture) may 
be placed in this category when evidence of carcinogenicity in 
humans is less than sufficient but there is sufficient evidence of 
carcinogenicity in experimental animals and strong evidence in 
exposed humans that the agent (mixture) acts through a relevant 
mechanism of carcinogenicity. 
Group 2 A “the agent (mixture) is probably carcinogenic to 
humans. The exposure circumstance entails exposures that are 
probably carcinogenic to humans”. This category is used when 
there is limited evidence of carcinogenicity in humans and 
sufficient evidence of carcinogenicity in experimental animals. In 
some cases, an agent (mixture) may be classified in this category 
when there is inadequate evidence of carcinogenicity in humans 
and sufficient evidence of carcinogenicity in experimental animals 
and strong evidence that the carcinogenesis is mediated by a 
mechanism that also operates in humans. 
Group 2 B: “the agent is possible carcinogenic to humans”. This 
category is used for agents, mixtures and exposure circumstances 
for which there is limited evidence of carcinogenicity in humans 
and less than sufficient evidence of carcinogenicity in experimental 
animals. It may also be used when there is inadequate evidence of 
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carcinogenicity in humans but there is sufficient evidence of 
carcinogenicity in experimental animals.  
Group 3: “the agent (mixture) is unclassifiable as to 
carcinogenicity in humans”. This category is used most commonly 
for agents, mixtures and exposure circumstances for which the 
evidence of carcinogenicity is inadequate in humans and 
inadequate or limited in experimental animals. Exceptionally, 
agents (mixtures) for which the evidence of carcinogenicity is 
inadequate in humans but sufficient in experimental animals may 
be placed in this category when there is strong evidence that the 
mechanism of carcinogenicity in experimental animals does not 
operate in humans. 
Group 4: the agent (mixture) is probably not carcinogenic to 
humans. This category is used for agents or mixtures for which 
there is evidence suggesting lack of carcinogenicity in humans and 
in experimental animals. 
The Italian CCTN classification (CCTN, 1991) was similar to that 
from IARC and EPA. The CCTN classification distinguished, until 
recently, 5 groups:  
  Group A: carcinogenic to humans 
  Group B: probably carcinogenic to humans (B1 limited evidence 
of carcinogenicity in epidemiological studies; B2 sufficient 
evidence of carcinogenicity in experimental animals) 
  Group C: possible carcinogenic to humans 
  Group D: unclassifiable as to carcinogenicity in humans. 
  Group E: probably not carcinogenic to humans, based on 
animals studies 
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The general categories recognized by the 1986 EPA guidelines 
were (U.S. EPA, 1986): 
 Group A - Carcinogenic to Humans:  
 Group B - Probably Carcinogenic to Humans: Agents with 
sufficient evidence (i.e., indicative of a causal relationship) from 
animal bioassay data, but either limited human evidence (i.e., 
indicative of a possible causal relationship, but not exclusive of 
alternative explanations; Group B1), or with little or no human data 
(Group B2). 
 Group C - Possibly Carcinogenic to Humans: Agents with limited 
animal evidence and little or no human data. 
 Group D - Not Classifiable as to Human Carcinogenicity: Agents 
without adequate data either to support or refute human 
carcinogenicity. 
 Group E - Evidence of Non-carcinogenicity for Humans: Agents 
that show no evidence for carcinogenicity in at least two adequate 
animal tests in different species or in both adequate epidemiologic 
and animal studies. 
The 2005 EPA Guidelines recommend expressing Weight of 
Evidence (WOE) by narrative statements rather than only 
hierarchical categories, and expressing them separately for the oral 
and inhalation routes. The statements are (U.S. EPA, 2005): 
  Carcinogenic to Humans 
  Likely to be Carcinogenic to Humans 
  Suggestive Evidence of Carcinogenic Potential 
  Inadequate Information to Assess Carcinogenic Potential 
  Not Likely to be Carcinogenic to Humans 
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The evaluation of the dose-response analysis, through the 
calculation of the carcinogenic potential, is required to look at the 
quantitative aspect of the cancer risk. Dose-response analysis 
determines the relationship between the dose and the type of 
adverse response and/or the probability or the incidence of the 
effect (dose-response assessment). The complexity of this step in 
many contexts derives mainly from the need to extrapolate results 
from experimental animals (mouse, rat) to humans, and/or from 
high to lower doses, including the extrapolation from high acute 
occupational levels to low chronic environmental levels.  
In the absence of human data to describe low-dose effects, two 
different approaches are most frequently used for dose-response 
analysis:  
- approach for “threshold” endpoint;   
- approach for “non threshold” endpoint. 
For non-cancer effects, it has been assumed that at low doses the 
body's natural protective mechanisms repair any damage caused by 
the pollutant, so a dose may exist below the minimum health effect 
level for which no adverse effects occur. The first dose of an agent 
which induces a response above zero (or above the control 
response) is usually referred to as a “threshold-dose”. The safe 
doses of chemicals associated with human diseases that are thought 
to act by a “threshold dose mechanism” are most frequently defined 
by applying safety factors to the no-observed-effect levels (NOEL) 
in animal bioassay studies. These so-called safe exposure levels are 
reported as acceptable daily intakes (ADIs) or reference doses 
(RfD). 
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For non-threshold effects (cancer), meaning that there may be some 
risks associated with any exposure, dose-response relationships 
based on observed incidence in humans and animals exposed at 
high doses are established and then extrapolation models are used 
to estimate the cancer risk associated with low-dose exposure.  
Essentially all chemicals can cause non-cancer adverse health 
effects if given at high enough doses. However, when the dose is 
sufficiently low, typically no adverse effect is observed. Thus, in 
characterizing the non-cancer effects of a chemical, the key 
parameter is the threshold dose at which an adverse effect first 
becomes evident. Doses below the threshold are considered to be 
safe, while doses above the threshold are likely to cause an effect 
(Grilli, 1992).  
The threshold dose is typically estimated from toxicological data 
(derived from studies of humans and/or animals) by determining 
the highest dose that does not produce an observable adverse affect 
and the lowest dose which produces an effect. These are referred to 
as the “no-observed-adverse-effect-level” (NOAEL) and the 
“lowest-observed-adverse-effect-level” (LOAEL), respectively.  
However, in order to be conservative (protective), non cancer risk 
evaluations are not based directly on the threshold exposure level, 
but on a value referred to as the Reference Dose (RfD). The RfD is 
an estimate of a daily exposure to the human population that is 
likely to be without an appreciable risk of deleterious effects during 
a lifetime.  
22 
 
 
The RfD is derived from the NOAEL, (or LOAEL if a reliable 
NOAEL is not available) by dividing the NOAEL by an 
“uncertainty factor”. If the data were from studies in humans and 
the observations were considered to be very reliable, the 
uncertainty factor may be as small as 1.0. However, the uncertainty 
factor is normally at least 10 and can be much higher if data are 
limited. The purpose of dividing the NOAEL or the LOAEL by an 
uncertainty factor is to ensure that the RfD is not higher than the 
true threshold level for adverse effects. Thus, there is always a 
“margin of safety” built into an RfD, and doses equal to or less 
than the RfD are nearly certain to be without any risk of adverse 
effect. Doses higher than the RfD may carry some risk, but because 
of the margin of safety, a dose above the RfD does not mean that 
an effect will necessarily occur.  
For cancer effects, the toxicity assessment process has two 
components. The first one is a qualitative evaluation of the weight 
of evidence that the chemical does or does not cause cancer in 
humans. For chemicals that are believed to be capable of causing 
cancer in humans, the second part of the toxicity assessment is to 
describe the carcinogenic potency of the chemicals. This is done by 
quantifying how the number of tumours observed in exposed 
animals or humans increases as the dose increases.  
Usually, it is assumed that the dose-response curve for cancer has 
no threshold (there is no dose other than zero that does not increase 
the risk of cancer), arising from the origin and increasing linearly 
until high doses are reached. Thus, the most convenient descriptor 
of cancer potency is the slope of the dose-response curve at low 
dose (where the slope is still linear). Estimating the cancer slope 
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factor is often complicated by the fact that observable increases in 
cancer incidence usually occur only at relatively high doses, 
frequently in the part of the dose-response curve that is no longer 
linear. It is necessary to use mathematical models to extrapolate 
from the observed high dose data to the desired slope at low doses.  
For carcinogen pollutants, such as dioxins (PCDDs/PCDFs), 
polycyclic aromatic hydrocarbons (PAHs), polychlorinated 
biphenyls (PCBs) and some heavy metals (HMs), the EPA model 
(2005) assumes there is no safe threshold dose below which there is 
no health risk. The health risk, measured as the probability of 
developing cancer during the entire lifetime (assumed to be 70 
years), is estimated by multiplying the exposure dose by the Cancer 
Slope Factor (CSF), which represents the estimate of the 
carcinogenic potency of the chemical. 
Three approaches have been recommended by WHO (WHO/IPCS, 
1998) for the quantitative assessment of cancer risk by inhaled 
PAHs: 
1. Benzo(a)pyrene (B(a)P) Toxicity Equivalence Factors (TEFs) 
approach, based on individual potencies relative to B(a)P in 
order to obtain a benzo(a)pyrene equivalent , 
2. Benzo(a)pyrene surrogate epidemiological approach, which 
assumes that B(a)P is an indicator of all PAHs in the mixture, 
3. comparative Potency Approach, which does not identify or 
quantify the individual compounds. 
The current study was based on the first approach. To evaluate the 
risk for human health of mixtures of PAHs, international and 
national Regulatory Agencies suggest to use equivalence factors 
(Potency Equivalence Factors, PEFs) (Table 2.1), which are 
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derived from carcinogenicity studies in small rodents and, where 
available, correlate the carcinogenic potential of each PAH or 
Nitro-PAH (NPAH) to that of B(a)P. The carcinogenic potential of 
B(a)P is assumed as 1 (WHO/IPCS, 1998).  
B(a)P was chosen as the reference compound as it  is considered 
the most appropriate indicator for the carcinogenic fraction of the 
large number of PAHs in air (WHO, 2000).  
The potency of many individual PAHs and NPAHs relative to that 
of B(a)P was estimated in order to obtain B(a)P equivalents 
(B(a)Peq) (WHO/IPCS, 1998). The B(a)Peqs represent the relative 
carcinogenic potential of the corresponding mixture of PAHs and 
NPAHs to B(a)P.  
The B(a)P equivalents are calculated multiplying the concentration 
of each component of the mixture by its PEF. Then the 
carcinogenic potency of the complete mixture of PAHs and NPAHs 
is estimated as the sum of each individual B(a)Peq with the 
following equation:  
B(a)Peq = ∑ (PAHi x PEFi) + ∑ (NPAHi x PEFi) 
In Table 2.1 the list of PEFs, which are currently available, is 
reported: 
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PAH PEF 
Benzo(a)pyrene 1 
Anthracene 0.28* 
Benz(a)anthracene 0.1 
Benzo(c) Phenanthrene 0.023* 
Benzo(b)fluoranthene 0.1 
Benzo(j)fluoranthene 0.1 
Benzo(k)fluoranthene 0.1 
Benzo[rst]pentaphene 1.1* 
Benzo(g.h.i)perilene 0.01# 
Ciclopenta(c.d)pyrene 0.012* 
Chrysene 0.01 
Dibenzo(a.h)acridine 0.1 
Dibenzo(a.j)acridine 0.1 
Dibenzo(a.h)anthracene 1# 
7H-Dibenzo(c.g)carbazole 1 
Dibenzo(a.e)pyrene 1 
Dibenzo(a.h)pyrene 10 
Dibenzo(a.i)pyrene 10 
Dibenzo(a.l)pyrene 10 
Phenanthrene 0.00064* 
Indeno[1.2.3-c.d]pyrene 0.1 
5-Methylcrhysene 1 
 
NPAH PEF 
Benzo(a)pyrene 1 
1,6-Dinitropyrene 10 
1,8-Dinitropyrene 1 
6-Nitrochrysene 10 
2-Nitrofluorene 0.01 
1-Nitropyrene 0.1 
4-Nitropyrene 0.1 
 
Table 2.1: Potency Equivalency Factors (PEFs) for PAHs and NPAH in B(a)P 
equivalent. Data from California EPA 1999 except (*) from MOE (Ministry of 
the Environment- Toronto-Canada) 1997 and (#) from CCME (Canadian Council 
of Ministers of the Environment) 2008. 
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The Cancer risk was assessed for each carcinogenic compound 
detected in the samples, whose Unit Risk (UR) value has been 
established by International Agencies (WHO, 2000 and CA-EPA, 
2005).   
The lifetime cancer risk (LCR) attributable to inhalation exposure 
was calculated by multiplying each UR estimated value by the 
average daily concentration of each compound: 
LCRi = Ci x URi 
The UR of each chemical corresponds to the excess lifetime cancer 
risk calculated as a result of the continuous exposure to B(a)Peq at 
a concentration of 1 ng/m3 in air over a lifetime of 70 years (U.S. 
EPA, 2011).  
The UR used for calculations are reported in Table 2.2.  
B(a)P 
Cancer UR 
1,1 x 10-6/ng/m3 (CA EPA, 2005) 
B(a)P equivalents 
Cancer UR 
8,7 x 10-5/ng/m3 [rounded to 1 x 10-4/ng/m3] 
(WHO, 2000) 
1 x 10-4/ng/m3 (CCTN, 1991) 
 
Table 2.2: Unit Risk for cancer risk assessment: B(a)P and B(a)P equivalents 
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CHAPTER 3 
Particulate Matter 
3.1 General characteristics of Particulate Matter  
Air pollution is already known to increase risks for a wide range of 
diseases, such as respiratory and heart diseases (Pope C.A., et al., 
2009). Studies indicate that in recent years exposure levels have 
increased significantly in some part of the world, particularly in 
rapidly industrializing countries with large populations. The most 
recent data indicate that in 2010, 223.000 deaths from lung cancer 
worldwide resulted from air pollution (Straif, K., et al. 2013). In 
terms of the global burden of all diseases attributable to air 
pollution, lung cancers account for less than 7% of the 3.22 million 
estimated deaths (Hamra, G.B., et al, 2014).  
Airborne air pollution is made up of particulate matter (PM) and 
hundreds of chemicals from natural sources and human activities 
(Brauer, M., et al, 2012; Fajerztajn et al., 2013) 
In October 2013, the International Agency for Research on Cancer 
(IARC) classified outdoor air pollution and particulate matter from 
outdoor air pollution as carcinogenic to humans (Group 1) 
(Loomis, D., et al, 2013) based on sufficient evidence of 
carcinogenicity in humans and experimental animals and strong 
mechanistic evidence.  
Particle pollution (also called particulate matter or PM) is the term 
for a mixture of solid particles and liquid droplets found in the air. 
PM is an air-suspended mixture of solid and liquid particles that 
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vary in time and space, in dependence on the source of emission, 
by the chemistry of the atmosphere and weather conditions (Pope 
and Dockery, 2006; Schauer et al., 1996). Among these particles, 
there are different components, such as sand, ash, dust, soot, acidic 
substances of various nature, plant substances, metal compounds, 
natural and artificial textile fibres, salts and elements such carbon 
or lead. 
Among the chemical-physical characteristics of particles, the size is 
the one used for classification due to its intrinsic importance. In 
fact the atmospheric deposition rates of particles, their residence 
times in the atmosphere and deposition patterns within the lung are 
strongly influenced by particles size.  
The behaviour of particles in the atmosphere and within the human 
respiratory system is determined largely by the physical properties, 
which have a strong dependence on size, varying from a few 
nanometres to tens of micrometres.  
The aerodynamic properties of particles determine how they are 
transported in air and how they can be removed from it. These 
properties also govern how far they get into the air passages of the 
respiratory system. Additionally, they provide information on the 
chemical composition and the source of particles.  
Airborne particles have irregular shapes and their aerodynamic 
behaviour is expressed in terms of the diameter of an idealised 
spherical particle known as aerodynamic diameter. The sampling 
and description of particles is based on this aerodynamic diameter, 
which is usually simply referred to as “particle size”. The 
aerodynamic diameter of a particle is the diameter of a spherical 
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particle having unit density and the same settling velocity from an 
airstream as the particle under study (Schlesinger 1985). 
Based on size, particulate matter is often divided into two main 
groups:  
 coarse fraction contains the larger particles with a size ranging 
from 2.5 to 10 µm (PM10 – PM2.5). 
 fine fraction contains the smaller ones with a size up to 2.5 µm 
(PM2.5).  
The particles in the fine fraction which are included in the 1 µm – 
0.1 µm range are called ultrafine particles (UFP or UP).  
One of the most important distinctions of particulate pollution is 
based on how the particles are introduced into the atmosphere:  
- primary particles, that are released directly from their 
source into the atmosphere. The main sources of primary PM are 
the land, the sea through soils carried by the wind and the 
generation of marine aerosol particles by the bursting of air bubbles 
in breaking waves. Road transport and industrial process are also 
major sources of primary particles. Primary PM and the precursor 
gases can have both man-made (anthropogenic) and natural (non-
anthropogenic) sources. Anthropogenic sources include 
combustion engines (both diesel and petrol), solid-fuel (coal, 
lignite, heavy oil and biomass) combustion for energy production 
in households and industry, other industrial activities (building, 
mining, manufacture of cement, ceramic and bricks, and smelting), 
(Schwarze et al., 2006) and erosion of the pavement by road traffic 
and abrasion of brakes and tyres. Agriculture is the main source of 
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ammonium. Natural sources include sea salt, naturally suspended 
dust, pollen and volcanic ash (EEA, 2012).  
- secondary particles are subsequently formed within the 
atmosphere as a result of chemical reactions, producing substances 
of low volatility, which consequently condense into solid or liquid 
phase, becoming PM.  Examples include sulphates and nitrates, 
formed from the oxidation of sulphur dioxide (SO2) and nitrogen 
dioxide (NO2) in the atmosphere to acid, which are then neutralised 
by atmospheric ammonia derived from agricultural sources. 
Carbonaceous particulates also contain a secondary fraction formed 
from the oxidation of volatile organic compounds (VOCs). 
Compared to primary particles, the chemicals processes involved in 
the formation of secondary ones are relatively slow and their 
persistence in the atmosphere is prolonged. The secondary particles 
are composed almost exclusively of particles of diameter less than 
2.5 µm (Kelly et al., 2012).  
The process by which secondary particles are formed is termed 
nucleation (Hamed et al., 2007); this term refers to the processes by 
which molecules of low volatility condense to form solid or liquid 
matter. There are two distinct types of nucleation process (Hinds, 
1999). The first is heterogeneous nucleation. Most secondary 
particle formation in the atmosphere occurs by this process, newly 
formed substances condense onto existing particles causing the 
growth of those particles. The condensation processes are most 
effective on small and medium sized particles, causing these to 
grow larger. The second process is called homogeneous nucleation. 
The best known process of homogeneous nucleation occurs when 
sulphuric acid (H2SO4) is formed from the atmospheric oxidation 
of SO2. Another phenomenon that leads to the growth of the 
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particles is the coagulation, which interact with those produced by 
nucleation. Coagulation can also affect products from 
homogeneous reactions occurring in the atmosphere.  
Figure 3.1 shows, in schematic form, the typical size distribution 
of airborne particles. Sizes range over several orders of magnitude. 
The smallest, freshly nucleated, particles are only 1–2 nm in 
diameter and contain only tens of molecules. At the other extreme, 
particles may be up to ~100 µm in diameter, which is comparable 
to a human hair. Particles as large as this rapidly settle out of the air 
and are of minor health significance because, although they can be 
inhaled, they do not generally penetrate beyond the nose and 
mouth. Consequently, air pollution research generally focuses on 
particles ≤10 µm in diameter, although it is important to recognise 
that larger particles are also present and contribute mass to ‘total 
suspended’ particles (TSP). 
 
Figure 3.1 Schematic diagram of the size distribution of airborne particles 
Adapted from: United Kingdom Department of Environment, Food, and Rural Affairs, 
Expert Panel on Air Quality Standards, 2004 
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3.2 Composition of Particulate Matter  
Airborne particles have a very diverse chemical composition that 
varies both in time and space. Air samples of particulate matter 
from urban areas from around the world typically show the same 
major components, although in considerably different proportions 
according to the sampling location (Harrison and Yin 2000). 
Airborne particles contain both major and minor components. The 
major components, normally, include the following:  
 Sulphate – arises mainly as a secondary component from 
atmospheric oxidation of SO2, although there may be a small 
primary component that arises from sea salt or mineral matter such 
as gypsum;  
 Nitrate – normally present as NH4NO3, which results from 
the neutralisation of HNO3 vapour by NH3, or as sodium nitrate 
(NaNO3), due to displacement of hydrogen chloride from NaCl by 
HNO3 vapour;  
 Ammonium – generally present in the form of ammonium 
sulphate ((NH4)2SO4) or NH4NO3; 
 Sodium and chloride – in sea salt; 
 Elemental carbon – black, graphitic carbon formed during 
the high temperature combustion of fossil and contemporary 
biomass fuels; 
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 Organic carbon – carbon in the form of organic 
compounds, either primary, resulting from automotive or industrial 
sources, or secondary, resulting from the oxidation of volatile 
organic compounds (VOCs);  
 Mineral components – crustal materials (rock and soil) are 
rich in elements such as aluminium, silicon, iron and calcium. 
These are generally present in coarse dusts that arise from, for 
example, wind-driven entrainment processes, quarrying, 
construction and demolition processes;  
 Water  
 Biological materials - bacteria, spores, pollens, debris and 
plant fragments; generally coarse in size, considered as part of the 
organic  
 Carbon component in most studies rather than as a separate 
biological component. 
Minor components include the following:  
 Trace metals – many metals such as lead, cadmium, 
mercury, nickel, chromium, zinc and manganese are used in 
metallurgical processes. Some occur as impurities or additives in 
fuels and others are used in industrial products. These and other 
uses cause emissions to the atmosphere, but concentrations are 
generally very small;  
 Trace organic compounds – although the total mass of 
organic compounds can comprise a significant part of the overall 
mass of particles, it is made up of a very large number of individual 
organic compounds, each of which is present at a very low 
concentration. Such organic compounds vary greatly in 
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composition and include aliphatic and aromatic hydrocarbons, 
heterocyclics and oxygenates such as aldehydes, ketones and 
carboxylic acids. Generally speaking, organic compounds that arise 
directly from fuel combustion processes have relatively high 
hydrogen to carbon ratio, whereas secondary organic compounds 
are more oxidised and polyfunctional carbonyl and carboxylic acids 
species are often present (Figure 3.2). 
 
 
Figure 3.2: Composition (%) of particulate typical of urban source (a), natural (b) and 
rural (c). (source Ministry of the Environment, Land and Sea) 
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3.3 Effects of Particulate Matter  
The respiratory system is the primary target of airborne particles 
which are inhaled and tend to accumulate in the airways. The 
comprehension of PM dosimetry is important to understand the 
toxic potential of PM. The respiratory tract can be divided into 
three main regions: the extrathoracic region, the tracheobronchial 
region and the alveolar or pulmonary region, where gas exchange 
occurs (U.S. EPA, 2004; Figure 3.3). The most important PM 
property driving deposition rate in the airways is particles size: in 
fact inhaled particles penetrate the respiratory system depending on 
mechanisms, such as inertial impact, sedimentation, diffusion, 
electrostatic attraction, which are related to particles size (U.S. 
EPA, 2004). Each region of the respiratory system presents typical 
clearance mechanisms that protect the organism from inhaled 
external agents. Filtration of the nasal passages is the main 
protective mechanism in the head region, while mucus secretion 
and ciliated cells act to remove particles and other external bodies 
in the tracheobronchial region. At the alveolar surface the clearance 
machinery is constituted by macrophages and type II pneumocytes 
that perform particles removal through their phagocytic activity. 
Particular attention should be finally paid to ultrafine particles 
which, thanks to their tiniest dimensions, may be able to escape 
macrophages removal and penetrate the alveolar-capillary barrier 
(Elder et al, 2006).   
The size of the particle is a main determinant of where in the 
respiratory tract the particle will come to rest when inhaled. Simple 
nomenclature is used to indicate the different degrees of relative 
penetration of a PM particles into the cardiovascular system 
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(Figure 3.3). Larger particles are generally filtered in the nose and 
throat via cilia and mucus (inhalable fraction). The particulate 
matter smaller than about 10 micrometers, referred to as PM10, can 
settle in the bronchi and lungs (thoracic fraction). Particles smaller 
than 2.5 micrometers, PM2.5, tend to penetrate into the gas 
exchange regions of the lung (alveolus) and very small particles 
(<100 nanometers) may pass through the lungs to affect other 
organs (respirable fraction) (Nemmar et al, 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.3 Disposition of particulate matter (PM) in the respiratory system (U.S. EPA 2004) 
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3.3.1 PM exposure and health effects  
Numerous epidemiological studies have established an association 
between short or long-term exposure to various airborne 
particulates and human mortality and morbidity (Chen and 
Lippmann, 2009; Rueckerl et al, 2011; Schwarze et al, 2006). 
Studies have found a significant correlation between excess 
mortality and short-term exposure to high concentration of ambient 
particulate matters (Bell and Davis, 2001; Schwartz and Markus 
1990). A population-based study on data collected in 6 US cities 
suggested an association between long-term exposure and human 
mortality (Dockery et al. 1993; Laden et al., 2000). Studies 
conducted in European and United States cities reported short-term 
exposure to PM10 to increase mortality of a value ranging from 
0.46 to 0.62 % (mean 0.5 %) for each 10 μg/m3 increment in the 
daily concentration (Cohen et al., 2004; Katsouyanni et al., 2001).  
Pope and colleagues (Pope et al., 2009) reported that PM2.5 
concentrations fell by a third from the early 1980s to 1990s across 
major US metropolitan areas, with each 10 µg/m3 reduction 
associated with an increase in life expectancy of 0.61 years (Pope 
et al., 2009).  
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A report from the prospective Cancer Prevention II study of the 
American Cancer Society, including about 500.000 participants, 
showed that each 10 µg/m3 increase in fine particulate air pollution 
was associated with a 6% increase in all-cause mortality, and with a 
9% increase in risk of cardiopulmonary mortality and 14% increase 
in risk of lung cancer (Pope et al., 2002).  
Recent long-term studies show associations between PM and 
mortality at level well below the current annual WHO air quality 
guideline level for PM2.5 (10 µg/m
3). Scientific evidence does not 
suggest a threshold of exposure to PM below which no adverse 
health effects would be anticipated (WHO, 2006a, 2006b, 2013). 
Another important epidemiological project, ESCAPE (European 
Study of Cohorts for Air Pollution Effects), was recently published. 
In the first study the association between long-term exposure and 
lung cancer was confirmed unequivocally (Raaschou-Nielsen et al., 
2013) whereas the second study was focused on the relationship 
between long-term mortality and air pollution (Beelen et al., 2013). 
In the first study the authors did not explore the causes of death. 
Recently it was reported an 18% increase in lung cancer incidence 
for each 5 µg/m3 increase in PM2.5 concentration in this cohort 
(Raaschou-Nielsen et al., 2013). The second study presents an 
analysis of pooled data from 22 longitudinal cohort studies across 
Europe, including more than 360.000 people followed up for an 
average of 13.9 years (Beelen et al., 2013). The authors show a 7% 
increase in natural cause mortality with each 5 µg/m3 increase in 
PM2.5 concentration (Beelen et al, 2013). These results are 
important because they present contemporary evidence from  
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diverse European populations exposed to PM2.5 concentration 
below the limits recommended in existing guidelines.  
Toxicological studies widely described the genotoxic effect of PM 
in humans (Møller et al., 2008; Billet et al., 2008; Oh et al., 2011). 
These results, together with the epidemiological evidences of lung 
cancer mortality for long-term exposure to PM2.5, suggest a role for 
DNA damage in PM related health effects (U.S. EPA, 2009). In 
agreement with epidemiology, fine PMs usually have a higher 
genotoxic potential compared to coarse fractions, in in vitro and in 
vivo models (Chackra et al., 2007; de Kok et al., 2005; Park et al., 
2005); moreover, PMs from industrialized, traffic and 
wood/biomass combustion areas have been found to exert a 
stronger effect on DNA (Shi et al., 2006; U.S. EPA, 2004).  
The high genotoxicity of these PMs is due to the particles 
composition and source, since particles derived from combustion 
processes have been found to be rich in metals and organic 
compounds, such as polycyclic aromatic hydrocarbons (PAHs), 
which are notorious genotoxic elements (Mehta et al., 2008). 
Actually, different mechanisms have been reported for PM-induced 
DNA damage, which include oxidative stress, organics metabolites 
formation and direct interaction of particles organic compounds 
with the DNA (Møller et al., 2008). Generation of ROS and 
consequent oxidative stress is widely recognized as an important 
toxicological mechanism in PM induced DNA double strand 
breaks/oxidation and possibly lung cancer (Shi et al., 2006; Møller 
et al., 2008).  
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High level of ROS production could lead to cell apoptosis and 
tissue damage, which may contribute to lung injury as seen in 
human or animal models following acute exposure to PM. ROS are 
able to initiate a series of redox signalling cascades to induce 
inflammatory responses and cytokine production found in both 
acute and chronic PM exposures (Akthar et al., 2010; Diabate et 
al., 2011). It has been demonstrated that transition metals (Cr, Cd, 
Ni and arsenic) and aldehydes present in PM can inhibit DNA 
damage repair mechanisms and this effect may enhance the 
genotoxic effect of PM and contribute to lung carcinogenesis 
(Mehta et al., 2008). 
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3.4 Polycyclic aromatic hydrocarbons (PAHs) 
A major group of chemicals that are found in complex mixtures are 
the polycyclic aromatic hydrocarbons (PAHs), a family of more 
than 1500 compounds (NTP, 2012) comprised of two or more 
fused aromatic rings, found both in their native and substituted 
form. PAH molecules are made up of three or more benzene rings. 
PAHs are ubiquitous environmental contaminants that are formed 
as a result of incomplete pyrolytic processes and to which humans 
are exposed through inhalation, ingestion and dermal absorption.  
In nature, PAHs are found in coal tar, crude oil, being also 
produced during combustion processes, such as forest fires and 
volcano eruptions (Rajput and Lakhani, 2009). In urban 
atmospheres, where the occurrence of PAHs in ambient air is of a 
particular concern, the majority of PAHs come from vehicular 
traffic emissions (Castellano et al, 2003; Gaga et al, 2012; Omar et 
al, 2002); however, PAHs are also emitted by trains and aircrafts. 
Stationary sources such as domestic heating, various industrial 
processes, waste incineration and energetic production systems are 
other significant contributors of PAHs to outdoor atmosphere 
(WHO, 1998). Due to their persistence in environmental matrices, 
as well as their adverse effects on human health, PAHs have been 
classified as priority pollutants by the US EPA – United States 
Environmental Protection Agency (U.S. EPA, 2004). PAHs are 
generally insoluble in water but can be solubilised in organic 
solvents or organic acids. This means that in aqueous environments 
PAH are generally found adsorbed on particulates and on humic 
matter; PAHs have an affinity for environmental matrices, such as  
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sediments and soils due to their greater hydrophobicity and through 
bioaccumulation and thus magnified in the food chain (WHO – 
IARC, 1998; Senthilkumar et al., 2008). 
Once released into the atmosphere, PAHs are partitioned between 
the PM and gas phases depending on their molecular weight (Chen 
et al., 2005; Furuuchi et al., 2007). As a result, larger molecular 
weight PAHs (< 4 rings) are almost exclusively bound to 
particulate matter, while low molecular weight PAHs (3 rings) can 
also be found dissolved in water (Wang et al., 2007; Khaiwal et al., 
2006).  
Links between human exposure to complex PAH mixtures and 
development of diseases including cancer, and respiratory and 
cardiovascular diseases have been described previously (IARC, 
2010; Pope et al, 2002). Despite their structural similarities, PAHs 
vary greatly in their carcinogenic potency, with both individual and 
complex mixtures of PAHs classified as possible or probable 
human carcinogens by the International Agency for Research on 
Cancer (IARC) (IARC, 2010).  
Subsequent to exposure, PAHs cross through cell membranes and, 
being lipophilic, undergo intracellular accumulation by 
concentrating in liquid droplets (Murphy et al., 2008). Studies from 
Ramesh et al have shown that PAHs can initiate and accelerate 
atherosclerosis and aneurysm in experimental animals through a 
cascade of biochemical events that involve oxidative stress and 
inflammation (Ramesh et al, 2015; Prins et al., 2012; Wang et al., 
2009).  
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3.4.1 Carcinogenic effects of PAHs  
The binding of PAHs to DNA, and the associated effects that occur 
as a result, is considered the major mechanism of PAH-induced 
mutagenesis and carcinogenesis. Like chemical carcinogens, PAHs 
require activation through a series of enzymatically-catalyzed 
reactions to form their active metabolites (Conney et al., 1982; 
Huberman et al.,1976; Sims et al., 1974). The cytochrome P-450 
family of enzymes, in particular CYP1A1, CYP1A2 and CYP1B1, 
are primarily involved in bioactivation of PAHs and formation of 
their reactive intermediates (Pelkonen and Nebert, 1982; Shimada 
and Fujii-Kuriyama, 2004). Many PAHs are ligands for the aryl 
hydrocarbons receptor (AhR), which has different roles in 
metabolism including regulation of the different bioactivating 
enzymes (Baird et al., 2005; Pàlkovà et al, 2015). The aryl 
hydrocarbon receptor (AhR) is a basic helix-loop-helix/Per-Arnt-
Sim (bHLH/PAS) transcription factor essential for adaptive 
responses to xenobiotics (Hao et al., 2013). Polycyclic aromatic 
hydrocarbons and halogenated aromatic hydrocarbons (HaHs) are 
by far the most common classes of AhR ligands (Denison et al., 
2003). For example, B(a)P is the most widely studied PAH. It is 
usually chosen as a marker for evaluating the toxicity of PAH 
mixtures, since the available toxicological data provide a sufficient 
basis for the conventional risk assessment, in which it can be 
assumed that the toxicity of all PAHs is equivalent to that of B(a)P. 
As a result of recent toxicological research, B(a)P has become 
classified as human carcinogen, group 1 (IARC 2012).  
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B(a)P is activated through a three step enzymatic mechanism 
involving (Jarvis et al., 2014) initial metabolism by CYP enzymes 
to B(a)P-7,8-epoxides, followed by conversion to B(a)P-7,8-diols 
by epoxide hydrolase, and final transformation to the ultimate 
reactive B(a)P-7,8-diol-9,10-epoxide metabolites, again by CYP 
enzymes (Conney, 1982) (Figure 3.4). This mechanism of 
activation has also been shown for other PAHs.  
Fig.3.4: Metabolism of benzo(a)pyrene 
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The tumorigenic and mutagenic activities of many PAHs have been 
linked to the ability of their diol epoxide metabolites to bind 
covalently to exocyclic amino groups on purine bases to form 
either stable bulky adducts or depurinating adducts which are 
released from DNA, leaving abasic sites (Rogan et al., 1993; 
Szeliga and Dipple, 1998). Following bioactivation and reaction 
with DNA, the PAH metabolites can induce mutation that either 
activate oncogenes or inactivate tumour suppressor gene as part of 
their carcinogenic mechanism (Jarvis et al., 2014).  
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CHAPTER 4  
Materials and Methods 
4.1 Experimental design 
Six different monitoring campaigns were performed by Arpa ER in 
the period 2011-2013 (Table 4.1). 
For each campaign, the toxicological characterization in BALB/c 
3T3 cells and the cancer risk assessment were performed.  During 
my training period at Harlan Cytotest Research, (Rossdorf, 
Germany), I have had the opportunity to perform the Bhas 42 CTA.  
Two different campaigns (Winter 2012 and Summer 2013) were 
evaluated with both cell transformation assays in order to compare 
the results obtained by the two testing methods.  
 
Table 4.1: Scheme of the tests used in the different monitoring campaigns 
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The experimental design for the toxicological characterization is 
reported in Figure 4.1.  
 
Figure 4.1 Study design for the toxicological characterization.  Green lines: activity 
performed by Arpa ER 
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In Figure 4.2, the experimental workflow for cancer risk 
assessment is reported. 
 
Figure 4.2 Experimental workflow for cancer risk assessment. Green lines: activity 
performed by Arpa ER. 
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4.2 Air samples collection  
For the toxicological characterization, the PM2.5 fraction was 
collected by the high volume air Flow PM2.5-HVS sampler, 
whereas Air Flow polyurethane foam (PUF), which could collect 
simultaneously gas (using PUF-polyurethane foam) and PM1, was 
used for PM1 sampling. Each filter was weighed daily before and 
after PM2.5 and PM1 collection in order to obtain the gravimetric 
data.  
For cancer risk assessment, the PM2.5 samples were collected at two 
sites located in the surroundings of Bologna (Emilia Romagna, 
Italy).  The sites were representative of different levels of 
environmental pollution. 
PM2.5 was collected daily on quartz-fiber filters (47 mm diameter) 
by low-volume air flow samplers (Skypost TCR TECORA), during 
the sampling campaigns I-IV, whereas high volume air flow 
sampler were used during campaigns V and VI. 
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4.3 Preparation of treatment solutions 
All the filters collected in one season were pooled to obtain a 
unique sample that was representative of the season.   
To obtain organic extracts, each pooled sample was extracted with 
acetone, using a Soxhlet apparatus, then reduced to dryness and 
dissolved in dimethylsulfoxide (DMSO) at 800 m3 equivalents/ml. 
The PM2.5 and PM1 inorganic fractions were extracted by 
sonication in ultrapure water and diluted in order to obtain stock 
solutions at 200 m3 equivalents/ml.  
The treatment solutions were prepared by diluting the stock 
solutions in the culture media immediately before use, at final 
doses ranging 1.5-12 m3 equivalents / 60 mm plate (0.5-4 m3 
equivalents/ml) for BALB/c 3T3 or 2-8 m3 equivalents/6 well plate 
(1-4 m3 equivalents/ml) for Bhas 42. The final concentrations of 
the vehicles DMSO or ultrapure water were 0.5% or 0.2%, 
respectively. 
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4.4 BALB/c A31-1-1 Cells 
The BALB/c 3T3 A31-1-1 cell line was purchased from the Health 
Science Research Resource Bank (Osaka, Japan). The cells were 
grown in Minimum Essential Medium (MEM) with 10% Fetal 
Bovine Serum (FBS), cryoconserved in MEM 10% FBS solution 
containing 5% DMSO and used for the CTAs at passages 3-5 from 
arrival. For the transformation assays, only sub-confluent cells 
(about 70% confluence) were used. The target cells were not 
maintained in culture beyond the third passage after thawing 
(Figure 4.3). 
Figure 4.3: Balb/c 3T3 A31-1-1 cells at different degrees of confluence. 10X 
magnification (from cellbank.nibio.go.jp/celldata/jcrb0601.htm) 
JCRB0601
BALB/C 3T3 A31-1-1
ATCC CLL-163
BALB/C 3T3 A31
52 
 
 
4.5 BALB/c A31-1-1 Cell Transformation Assay 
4.5.1 Cytotoxicity test 
The cytotoxicity assay was performed by seeding exponentially 
growing BALB/c 3T3 A31-1-1 cells at 250 cells/60-mm dish in 
five replicates for each treatment. Cells were then exposed to 
different concentrations of the environmental samples (1.5 – 12 m3 
equivalents) for 48 h. At the end of this period, the treatment was 
removed and fresh culture medium was added to the plates. Cells 
were maintained in culture for 8-10 days, then fixed with methanol, 
stained with 10% aqueous Giemsa and scored for colony 
formation. Only colonies containing more than 50 cells were 
counted (IARC/NCI/EPA Working Group, 1985; Franken et al., 
2006). Untreated BALB/c 3T3 A31-1-1 cells and solvent-treated 
cells were used as negative controls.  
The results were expressed as the mean number of colonies/plate ± 
standard error (SE), the absolute clonal efficiency (ACE), i.e. the 
fraction of cells which survived chemical treatment with respect to 
the number of seeded cells, and the relative clonal efficiency 
(RCE), which estimates the percent reduction of cell clonal 
efficiency in treated groups as compared to that of the relative 
control (vehicle-treated cells).  
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4.5.2 Morphological Cell transformation assay 
Cells were seeded at a density of 3 x 104 cells/60 mm dish, 
incubated for 48 h and then exposed to the PM2.5 and PM1 extracts 
at concentrations ranging from 1.5 to 12 m3 equivalents. Ten 
replicates were carried out. Untreated BALB/c A31-1-1 cells and 
solvent-treated cells were used as negative controls. Positive 
controls were represented by cells treated with the well-known 
carcinogen, 3-MCA, final concentration 4 µg/ml. After 48 h, the 
treatment medium was removed and replenished with fresh normal 
culture medium. Cells were maintained in culture for 4 weeks, with 
medium changes twice a week, then fixed with methanol, stained 
with 10% aqueous Giemsa and scored for foci formation (Figure 
4.4). 
 
Figure 4.4: Plates from a cell transformation experiment 
A – negative control - cells treated with solvent  (DMSO). 
B – positive control - cells treated with carcinogen (3-MCA). 
A B 
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4.5.3 Evaluation Criteria for Morphological Cell 
Transformation 
The scoring of foci was carried out according to the recommended 
guidelines (Sasaki et al., 2012; Colacci et al., 2011). Only foci 
considered as positive (type III) (Figure 4.5) showing deeply 
basophilic, dense multilayering of cells, random cell orientation at 
all parts of the focus edge, invasion into the surrounding contact-
inhibited monolayer and domination of spindle-shaped cells were 
counted.  Unlike the parental cells, cells isolated from foci type III 
are tumorigenic when injected into the host mice (Kakanuga et al., 
1985; Colacci et al., 1993).  
 
Figure 4.5: transformed foci induced by 3-MCA (40X). 
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The result of the CTAs are considered acceptable when: (i) the cell 
transformation was significantly increased in the positive controls; 
(ii) no significant increase in the cell transformation was observed 
in the negative control (DMSO); (iii) the total number of 
transformed foci detected in the positive control plates was at least 
2-time higher than the number of foci detected in the negative 
control.  
Results were reported as the number of positive control (plate with 
foci/scored plates); the mean number foci/plate ± standard error 
(SE); and the transformation frequency (TF), calculated on the cells 
that survived after chemical exposure. TF is expressed as a function 
of the total number of foci for treatment divided by the number of 
surviving cells estimated from the clonal efficiency observed in the 
cytotoxicity assay performed in parallel with the transformation 
test (Schechtman, 1985).  
4.5.4 Classification criteria  
According to the classification criteria as previously established 
(Ohmori et al., 2005; Hayashi et al., 2008; Mascolo et al., 2010; 
Sakai et al., 2010), the CTA test is considered positive when the 
following criteria are fulfilled:  
- the increase of the mean number of transformed foci/plate was 
statistically significant, at 99% confidence level, when two or more 
doses induced positive effects; 
- the increase of the TF in the treatment groups was at least two- 
fold higher than that detected in the solvent control; 
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- the toxicity in the treatment groups was less than 90%, i.e. the 
surviving cells in the treatment group were more than 10% of the 
treated population.  
If only the first criterion but not the second one was fulfilled, the 
test would be considered equivocal. If either the first criterion or 
the second criterion were fulfilled but not the third one, the test 
would be considered as misleading positive. Negative samples 
were those where no statistically significant increase of 
transformed foci was observed at any assayed dose.  
4.5.5 Statistical analysis 
The difference between the mean colony numbers in the treated 
groups compared to the control group was evaluated by the Student 
t-test. Significant differences in the ACE of cells exposed to the 
chemical treatments were tested by the z-test for comparison of two 
proportions. The RCE was analyzed by the Chi-square test of 
significance in 2 x 2 contingency tables. The significant percentage 
of plates with foci with respect to scored plates was calculated 
according to the Fisher – Yates test of significance in 2 x 2 
contingency tables. The statistical analysis of the foci distribution 
was performed by the Mann-Whitney test (Mann – Whitney 
unpaired t-test). The transformation frequency (TF) significance 
was analyzed by the comparison of the Poisson rates, after 
verifying that the TF values would fit the Poisson distribution. The 
linear regression analysis and the Cochran – Armitage test for 
positive trends were applied to the TF dose-response curve in the 
cell transformation assay.  
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4.6 Bhas 42 Cells 
The Bhas 42 cell line was purchased from the Health Science 
Research Resource Bank (Osaka, Japan). The cells were grown in 
Minimum Essential Medium (MEM) supplemented with 10% fetal 
bovine serum and 1% 100x Penicillin/Streptomycin solution, 
cryoconserved in MEM 10% FBS solution containing 5% 
dimethylsulfoxide (DMSO) and used for the CTAs. Dulbecco’s 
modified Eagle’s medium/Ham’s F12 supplemented with 100 
units/ml of penicillin, 100µg/ml of streptomycin and 5% FBS was 
used for the transformation assay.  
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4.7 Bhas 42 Cell transformation assay  
The current protocol consist of two assay components, the 
initiation assay and promotion assay for examining tumour-
initiating activity and tumour-promoting activity of chemicals, 
respectively (Asada et al., 2005; Sakai et al., 2010).  
In the initiation assay the cells are treated at the beginning of the 
growth phase to allow for fixation of the induced DNA damage, 
whereas in the promotion assay the cells are repeatedly treated at 
stationary phase to provide growth advantages for anomalous cells.  
4.7.1 Cell growth assay 
Initiation assay  
Cells were seeded at a density of 2 x 103 cells/ml and distributed 
into each well of 6-well micro plates in a 2 mL volume (4000 
cells/well, day 0), incubated for 24 h and then exposed to the PM2.5 
and PM1 organic extracts at concentrations ranging from 2 to 8 m
3 
equivalent/well (1-4 m3/ml). Three wells were prepared for each 
treatment group. On day 4, the medium containing the test 
chemical was replaced with the fresh medium DF5F. On day 7 the 
cells were fixed with 10% formalin and stained with a 0.1% Crystal 
Violet (CV) solution for 15 min. CV was extracted from the stained 
cells with 2 ml of dye extraction solution (containing 0.02 mol/HCl 
and 50% ethanol), and the OD is measured at a wavelength 
between 540-570 nm. The relative cell growth of cultures treated 
with a chemical is calculated as follows: 
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relative cell growth (%) = [( Treatment – Blank)/(Control – Blank)] 
X 10 
Promotion assay  
In the cell growth component of the promotion assay, cells were 
seeded at a density of 7 x 103 cells/ml (14 x 103 cells/well, day 0) 
and on day 4 the culture medium was replaced with a medium 
containing the different doses (2 - 8 m3/well) of PM extracts. On 
day 7 the cells were fixed, stained with CV and the CV extracted 
from cells was measured as previously described.  
4.7.2 Cell transformation test  
Initiation assay  
Cells were seeded at a density of 2 x 103 cells/ml and distributed 
into each well of 6-well micro plates in a 2 ml volume (4 x 103  
cells/well, day 0). On day 1, 24 h after seeding, the cells were 
treated for three days in the same way as the cell growth assay. The 
medium was changed on day 4, 7, 10, and 14. On day 21, the cells 
were fixed with methanol and stained with 5% Giemsa solution 
(Figure 4.6) 
Promotion assay  
The promotion assay was carried out as described for the initiation 
assay, except for the number of cell plated and timing of chemical 
treatment. Cells were plated at 14 x 103 cells/well and cultured for 
4 days without a medium exchange. On day 4, day 7, day 10 the 
culture medium was replaced with different concentrations of the 
test chemical and the treatment in the promotion phase was 
continued until day 14 (Figure 4.7). 
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The known tumour initiator MCA (1 µg/ml final concentration) and 
the known tumour-promoter TPA (50 ng/ml final concentration) 
were used as positive controls in the initiation and the promotion 
assay, respectively. MCA and TPA were dissolved in dimethyl 
sulfoxide (DMSO), which serves as the vehicle for these two 
positive agents.   
 
Figure 4.6: Schematic protocol of cell growth assay and transformation assay in the 
initiation assay. 
Figure 4.7: Schematic protocol of cell growth assay and transformation assay in the 
promotion assay.  
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4.7.3 Counting of transformed foci and statistical analysis 
The transformed foci were judged on the basis of the following 
morphological characteristics: 
 more than 100 cells; 
 spindle-shaped cells whose morphology was distinctly different 
from the contact – inhibited monolayer cells; 
 deep basophilic staining; 
 random orientation of cells; 
 dense multilayering of cells; 
 invasive growth into the monolayer of surrounding contact – 
inhibited cells 
 
 
Figure 4.8: Transformed foci induced by 3-MCA (40X). 
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Test substance – induced transformation frequency (number of 
transformed foci/well) in the 6-well method is statically analyzed 
by multiple comparison using the one-sided Dunnett test (p<0.05, 
upper side).  
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4.8 Risk Assessment  
Cancer risk analysis associated with lifetime inhalation of airborne 
environmental pollutants was performed on chemical parameters 
measured by Arpa ER during six different sampling campaigns, 
which are carried out in different seasons. The cancer risk 
assessment was focused on several chemicals extracted from PM2.5, 
such as polycyclic aromatic hydrocarbons (PAH, ng/m3) and 
nitroPAHs (NPAH, ng/m3) extracted from PM2.5. 
The following 33 PAHs and NPAHs were included in the total 
PHAs estimation (Table 4.2). Among the 33 PAHs which were 
included in the total PHAs estimation, 15 PAHs were assessed 
using the potency equivalency factor (PEF) approach. The same 
PAHs and NPAHs were measured in all sampling campaigns. 
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Chemical name IARC classification PEF 
PAHs   
Benzo[a]pyrene 1 1 
Acenaphthene 3 - a 
Acenaftilene  - a 
Anthracene 3 - a 
Benz[a]anthracene 2B 0.1 
Benzo(b+j)fluoranthene  2B 0.1 
Benzo[e]pyrene 3 - a 
Benzo[ghi]perylene 3 0.01# 
Benzo[k]fluoranthene 2B 0.1 
Cyclopenta[cd]pyrene 2A 0.012* 
Chrysene 2B 0.01 
Dibenz[a,c]anthracene 3 1# 
Dibenz[a,h]anthracene 2A - a 
Dibenzo[a,e]fluoranthene 3 - a 
Dibenzo[a,e]pyrene 3 1 
Dibenzo[a,h]pyrene 2B 10 
Dibenzo[a,i]pyrene 2B 10 
Dibenzo[a,l]pyrene 2A 10 
Fluoranthene 3 - a 
Fluorene 3 - a 
Indeno[1,2,3-cd]pyrene 2B 0.1 
Naphthalene 2B - a 
Phenanthrene 3 - a 
Pyrene 3 - a 
Perylene 3 - a 
N-PAHs   
9-Nitroanthracene 3 - a 
3-Nitrobenzanthrone 2B - a 
7-Nitrobenz[a]anthracene 3 - a 
6-Nitrobenzo[a]pyrene 3 - a 
6-Nitrochrysene 2A 10 
9-Nitrofenantrene  - a 
2,3-Nitrofluoranthene  - a 
1-Nitropyrene 2A 0.1 
Table 4.2: List of PAHs and NPAHs with relative PEFs (Potency Equivalency Factors) a: 
absence, data from California EPA 1999 except (*) from MOE (Ministry of the 
Environment- Toronto-Canada) 1997 and (#) from CCME (Canadian Council of 
Ministers of the Environment) 2008. 
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Such determinations were used in order to evaluate the lifetime 
cancer risks associated with air inhalation in two different sites 
(rural site and urban site), by the relative potency of compounds 
belonging to the same chemical class and the specific unit of 
carcinogenic risk. 
The daily mean concentrations of chemicals in PM2.5 were 
measured in different sampling periods (2011-2014). When the 
amount of the chemical present in the analyzed sample was lower 
than the detection limit (LOD), the half of the LOD (LOD/2) was 
taken into account, in accordance with US EPA criteria (US EPA, 
2000). The LODs for PAHs and NPAHs were rounded to 0.2 ng 
and 5 ng, respectively. 
For the determination of the inhalation exposure, the daily 
measurements of each chemical belonging to the same chemical 
class were summed together to obtain daily class total values. 
Statistical analyses were performed by Student t-Test to compare 
the daily mean concentrations ± standard deviation (SD) from the 
different sites (urban vs rural sites). 
Furthermore, in order to properly assess health risks, certain groups 
of chemicals were assessed as mixtures. Specifically, carcinogenic 
PAHs were assessed using the toxic equivalency factors (TEF) 
approach. TEFs for carcinogenic PAHs represent their toxicity 
relative to B(a)P (WHO/IPCS, 1998).  
So, the air concentrations of pollutants from each site were 
evaluated as B(a)Peq. The potency of many individual PAHs and 
NPAHs relative to that of B(a)P was estimated in order to obtain 
the B(a)P equivalents. 
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All these data were compared to limits and UR (unit risk) values 
for inhalation exposures derived from the available literature 
(WHO, 2000 and CA-EPA, 2005) (Table 2.2).  
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CHAPTER 5  
Results  
5.1 Cell Transformation Assay in BALB/c 3T3 A31-1-
1 cells 
The organic and aqueous extracts from the collected samples were 
evaluated for cytotoxicity and transforming activity in order to 
identify dose-related effects possibly associated with different 
aerodynamic diameters or airborne chemicals component. The cell 
transformation assay (BALB/c 3T3 CTA) was performed treating 
cells with equivalent doses (m3) of organic and aqueous extracts of 
PM2.5 and PM1 in order to highlight possible differences in the 
transforming or cytotoxic potential of the mixtures of chemicals 
associated with particles with different aerodynamic diameters. The 
results from CTA conducted with PM2.5 and PM1 samples have 
been accepted, as all of the established acceptability criteria were 
fulfilled.  
Before the experimental study, particular attention was paid to the 
choice of the cell model and the reference protocol 
The validation study of the cell transformation assay in vitro with 
BALB/c 3T3 cells, coordinated by EURL-ECVAM (Corvi et al., 
2012), has in fact lead to the development of a standardized, 
transferable and repeatable protocol, which will form the basis of 
the testing Guideline OECD. 
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The protocol used by the Laboratory of Experimental Toxicology 
in previous projects of air quality monitoring protocol (in-house 
protocol) (Mascolo et al., 2010) differed from the ECVAM 
validated protocol (Figure 5.1) for the following features: 
 seeding - the cell number is increased (3 x 104 instead of 1 x 
104 in 60 mm diameter plates) (Matthews et al., 1993); 
 time treatment – the cells were treated on Day 2 instead of Day 
1 (i.e. 48 h after seeding instead of 24h) (Matthews et al., 
1993);  
 culture medium – the cells were maintained in standard media 
from Day 7 to the end of the experiment instead of the ECVAM 
protocol modified media (enriched basal medium supplemented 
with 2% fetal bovine serum) (Tsuchya et al., 1995; 2010).  
 number and type of plates. 
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Figure 5.1: Comparison of the “in house” protocol and the ECVAM protocol  
The performance of the two protocols of the cell transformation 
assay was compared by using the organic extract PM2.5 collected 
during the I autumn campaign (Figures 5.2 and 5.3).  
The results obtained by treating cells with the collected PM2.5 
samples have been reported in Figure 5.2 and 5.3. On the basis of 
the results obtained both in term of the cytotoxic effect that in term 
of mean number of detected foci (Figures 5.2 and 5.3), no 
significant differences between the two protocols under  
comparison have been demonstrated. For this reason, the in-house 
protocol for cell transformation assay was chosen to perform the 
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evaluation of each collected sample, in order to compare with the 
results obtained in previous projects. The study continued 
analyzing the cytotoxic and transformation effects of the organic 
and inorganic extract of PM2.5 and PM1 collected during the 
various monitoring campaigns.  
 
Figure 5.2: I autumn campaign - Cytotoxic effects induced by organic extract of PM2.5; 
RCE = relative clonal efficiency  
** significantly different (p<0.01) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
 
Figure 5.3: I autumn campaign - Transformation frequency (TF) induced by organic 
extract of PM2.5  
** significantly different (p<0.01) from control DMSO (solvent-treated-plates) at the 
Poisson test 
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5.2 Evaluation of toxicity in BALB/c 3T3 A31-1-1 
The study continued analyzing the cytotoxicity and transformation 
effects induced by the organic and inorganic extract of PM2.5 and 
PM1 collected during the various monitoring campaigns.  
The following figures (Figures 5.4 – 5-9) report the relative clonal 
efficiency (RCE), which estimates the percent reduction of cell 
clonal efficiency in treated groups as compared to that of the 
relative control (DMSO).  
 
Figure 5.4: RCE relative clonal efficiency cytotoxicity effects induced by organic extract 
of PM 1 I autumn campaign 
** significantly different (p<0.01) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
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Figure 5.5: RCE relative clonal efficiency cytotoxicity effects induced by organic extract 
of PM 1 and PM 2.5 II summer campaign 2012 
** significantly different (p<0.01) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
* significantly different (p<0.05) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
 
 
Figure 5.6: RCE relative clonal efficiency cytotoxicity effects induced by organic extract 
of PM 1 and PM 2.5 III Autumn campaign 
** significantly different (p<0.01) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
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Figure 5.7: RCE relative clonal efficiency cytotoxicity effects induced by organic extract 
of PM 1 and PM 2.5 IV Winter campaign 
** significantly different (p<0.01) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
* significantly different (p<0.05) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
 
Figure 5.8:RCE relative clonal efficiency cytotoxicity effects induced by organic extract 
of PM 1  and PM 2.5 V Summer campaign 
** significantly different (p<0.01) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
* significantly different (p<0.05) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables. 
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Figure 5.9: RCE relative clonal efficiency cytotoxicity effects induced by organic extract 
of PM 1 and PM 2.5 VI Autumn campaign 
** significantly different (p<0.01) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
* significantly different (p<0.05) from control DMSO (solvent-treated-plates) at the Chi-
square test of significance in 2x2 contingency tables 
All the assayed PM2.5 and PM1 organic extract samples were able to 
induce significant dose-dependent cytotoxicity. All the winter and 
summer samples of organic extract of PM1 and PM2.5 were toxic at 
least at the two higher doses (6 m3 and 12 m3) (Figures 5.2 and 5.4 
- 5.9). 
The samples  collected during the I campaign (autumn 2011) were 
the most toxic, as all the treatment doses were found to induce 
highly significant cytotoxic effects (Figure 5.2).  
All the assayed organic extracts induced a dose-related reduction in 
the cloning efficiency, but the degree of the toxic response which 
was provided depended on the analyzed sample and was mainly 
associated with the season of sampling (Graphic 5.1 a-b). In 
general, the worst scenario seems to be associated with autumn 
2011 both for PM1 and PM2.5 organic extracts.  
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The differences in behaviour between the samples derived from 
different campaigns in term of cellular toxicity were confirmed 
when the RCEs were related with the amount of particulates (PM, 
µg/plate) corresponding to the m3 equivalents present in the 
treatment solutions (Graphic 5.1 c-d).  
 
Graphic 5.1: Cytotoxic effects of organic extracts of PM1 and PM2.5 in BALB/c 3T3 
A31-1-1. 
a-b: m3 equivalents/plate; c-d: PM, µg/plate 
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Overall, the data demonstrated that the observed toxicity was 
associated with the concentrations of PM present in the sample, 
which varied with the sampling season. Referring to the organic 
extracts, the winter samples were always associated with the worst 
scenarios, in terms of both toxicity and concentration of particles.  
Results from our experiments did not show any significant 
difference between PM2.5 or PM1 organic extracts in eliciting 
cytotoxic or transforming effects, even if biological effects are 
usually associated with the fine and ultrafine fractions. 
In order to possibly relate the observed toxic effects to the presence 
and/or the amount of micro-pollutants in the collected PM samples, 
the extracts were chemically characterized, focusing on micro-
pollutant such as PAHs and NPHAs, which have been 
associatedwith the adverse effects of the inhalable fraction of PM 
(toxicity,mutagenicity and carcinogenicity) and are of concern for 
public health (Sun et al., 2014). In numerous studies the 
concentrations of PAHs or NPAHs measured in air samples have 
also been linked with the toxicological effects of particulate matter 
and organic extracts of particulates (Colacci et al., 2007; Kang et 
al., 2010). It was observed that some PAHs and NPAHs induced 
transformation in BALB/c 3T3 cells or in Bhas 42 cells (Asada et 
al., 2005; Sasaki et al., 2010; Ohmori et al., 2013).  
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When the cell toxicity observed in the different campaigns was 
related to the overall amount of PAHs and NPAHs (ng/plate) 
present in each treatment extract, the seasonal trends previously 
observed were confirmed (Graphic 5.2). 
 
Graphic 5.2: Cytotoxic effects of organic extracts of PM1 and PM2.5 in BALB/c 3T3 
A31-1-1 
a-b: PAH (ng/plate) ; c-d: NPAHs (ng/plate)  
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As for the aqueous extracts, cytotoxic effects and even dose-
dependent responses were not observed after the treatment with 
both the PM1 and PM2.5.. The values of ECR which were 
significantly different from the controls (Figure 5.10 - 5.15) were 
not related to the treatment doses and were higher than the 80%. 
Figure 5.10: Cytotoxicity induced by aqueous extracts of PM 1 and PM 2.5 - I autumn 
campaign. RCE= relative clonal efficiency 
* significantly different (p<0.05) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables 
** significantly different (p<0.01) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables 
 
Figure 5.11: Cytotoxicity induced by aqueous extracts of PM 1  and PM 2.5 - II Summer 
campaign.  RCE= relative clonal efficiency.  
* significantly different (p<0.05) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables 
** significantly different (p<0.01) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables. 
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Figure 5.12: Cytotoxicity induced by aqueous extracts of PM 1 and PM 2.5 - III Autumn 
campaign.  RCE= relative clonal efficiency.  
* significantly different (p<0.05) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables 
** significantly different (p<0.01) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables 
 
 
Figure 5.13:  Cytotoxicity induced by aqueous extracts of PM 1 and PM 2.5 - IV Winter 
campaign.  RCE= relative clonal efficiency. 
* significantly different (p<0.05) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables 
** significantly different (p<0.01) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables 
80 
 
 
 
Figure 5.14: Cytotoxicity induced by aqueous extracts of PM 1 and PM 2.5 – V Summer 
campaign.  RCE= relative clonal efficiency. 
** significantly different (p<0.01) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables 
 
 
Figure 5.15: Cytotoxicity induced by aqueous extracts of PM 1  and PM 2.5 - VI Autumn 
campaign.  RCE= relative clonal efficiency. 
** significantly different (p<0.01) from control (solvent-treated-plates) at the Chi-square 
test of significance in 2x2 contingency tables 
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5.3 Evaluation of the transforming potential in 
BALB/c 3T3 A31-1-1 cells 
The results from the CTAs performed with the PM2.5 and PM1 
organic samples were accepted, since all the established 
acceptability criteria had been fulfilled. The positive control (3-
MCA 4 µg/ml) induced a significant increase of the transformation 
frequency, while the negative control (DMSO 0.5%) did not induce 
any significant increase of the cell transformation. Also, the total 
number of transformed foci detected in the positive control plates 
was at least 2 times higher than the number of foci observed in 
DMSO-treated plates.  
No significant increase in the average number of transformed 
foci/plate or in the transformation frequency was observed in the 
plates treated with summer and winter-autumn PM2.5 organic 
samples. The treatment with the extract of PM2.5 collected during 
the I campaign (autumn 2011) did not induce any significant 
increase in the mean number of foci/plate; however, the 
transformation frequency was increased in cell treated with the 
highest dose of the sample (Figure 5.16).  
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Figure 5.16: I autumn campaign - Transformation frequency (TF) induced by organic 
extract of PM 2.5 I autumn campaign 
** significantly different (p<0.01) from control DMSO (solvent-treated-plates) at the 
Poisson test 
This result may suggest that the increase in the transformation 
frequency was a consequence of the high toxicity of this sample. 
Therefore, all the PM2.5 organic samples (Graphic 5.3) were 
considered negative in the BALB/c 3T3 A31-1-1 cell 
transformation assay.  
 
Graphic 5.3: Transformation frequency (TF) induced by organic extract of PM 2.5 in in 
BALB/c 3T3 A31-1-1 
83 
 
All the aqueous extracts, as well as the PM1 organic extracts, failed 
in inducing cell transformation in our study (data not shown). 
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5.4 Bhas 42 Cell Transformation Assay  
Two different monitoring campaigns (summer 2013 and autumn 
2012) were analyzed with the Bhas 42 Cell Transformation Assay. 
The samples were assayed to detect the initiating potential of 
organic particulate extracts (PM1 and PM2.5). Moreover, the 
promoting potential of environmental samples was evaluated by the 
determination of the occurrence of transformed foci as a 
consequence of the repeated treatment (total: 10 days) of Bhas 42 
cells. 
The highest final concentration of the treatment solutions was 4 
m3/ml, which is the same that was used in the BALB 3T3 CTA. So, 
the highest dose of PM that was provided in each well was 8 m3. In 
the initiation assay, the Bhas 42 cells were exposed to equal 
volumetric concentrations (2-8 m3) of organic extracts from PM2.5 
or PM collected during autumn 2012 (III campaign) and summer 
2013 (V campaign). In the promotion assay, the same final 
concentrations of PM extracts were provided at each administration 
of the treatment.  
The cytotoxicity was determined by crystal violet staining. The 
transformation frequency was calculated as the mean number 
foci/plate ± standard deviation. 
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5.4.1 Initiation assay: results from the autumn campaign 2012  
The results from the initiation phase of the cell transformation 
assay for the III campaign (autumn 2012) were shown in Table 5.1 
and Figure 5.17. 
Table 5.1: Cell growth assay PM1 and PM2.5 III campaign autumn 2012 
(a) % of cell growth compared to that of solvent control 
 
Figure 5.17: Effects of the treatment with PM2.5 and PM1   III campaign autumn 2012 on 
the transformation rate of Bhas 42 cells (initiation) 
*Significantly different (p<0.05) from control DMSO at the Dunnet test 
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The initiating treatment with the organic extracts of the III 
campaign (autumn 2012) induced a cytotoxic dose-related effect. 
The reduction of the cell viability was about 50% at the highest 
doses (6 m3 and 8 m3) (Table 5.1). 
The transformation frequency was affected by the PM organic 
extracts, as demonstrated by the significant increase of type III foci 
at the doses 4, 6 and 8 m3 (p < 0.05, Dunnet test) (Figure 5.17).  
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5.4.2. Promotion assay: results from the autumn campaign 
2012  
Table 5.2: Cell growth assay PM2.5 5 III campaign autumn 2012 
(a) % of cell growth compared to that of solvent control 
 
Figure 5.18: Effects of the treatment with PM2.5 III campaign autumn 2012 on the 
transformation rate of Bhas 42 cells (promotion) 
*Significantly different (p<0.05) from control DMSO at the Dunnet test 
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The promotion phase assay was conducted only for PM2.5 extracts. 
No cytotoxic effects were observed at the end of the treatment 
period up to the highest applied concentration as evaluated both 
with crystal violet staining and microscopical observation. The 
significant increase of type III foci was induced at doses 4, 6 and 8 
m3 (p < 0.05, Dunnet test) (Table 5.2 and Figure 5.18).  
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5.4.3 Initiation assay: results from the summer campaign 2013  
Table 5.3: Cell growth assay PM2.5  and PM1 1 V campaign summer 2013 
 (a)% of cell growth compared to that of solvent control 
 
Figure 5.19: Effects of the treatment with PM2.5 and PM1  V campaign summer 2013 on 
the transformation rate of Bhas 42 cells (initiation) 
*Significantly different (p<0.05) from control DMSO at the Dunnet test 
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The summer extracts did not induce any toxic effect in Bhas 42 
cells treated from Day 1 to Day 4 in the initiation assay. In these 
experimental conditions, neither a statistically significant nor a 
concentration-dependent increase of type III foci was observed in 
the transformation assay after treatment with the test items. The 
negative and the solvent control did not affect the number of type 
III foci, whereas the positive control MCA (4µg/ml) induced a 
statistically significant increase in the number of type III foci, thus 
ensuring the validity of the study. 
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5.4.4 Promotion assay: results from the summer campaign 2013 
Table 5.4: Cell growth assay PM2.5 and PM1 V campaign summer 2013 
(a) % of cell growth compared to that of solvent control 
 
Figure 5.20: Effects of the treatment with PM2.5 and PM1 V campaign summer 2013 on 
the transformation rate of Bhas 42 cells (promotion) 
*Significantly different (p<0.05) from control DMSO at the Dunnet test 
 
In the promotion phase, no cytotoxicity was observed while the 
number of type III foci was increased after the repeated treatment 
with both PM1 and PM2.5 extracts at doses 4 m
3, 6 m3 and 8 m3 (p < 
0.05) (Table 5.4, Figure 5.20). 
92 
 
5.5 Risk assessment  
5.5.1 Chemical characterization  
The cancer risk assessment was focused on several chemicals 
extracted from PM2.5, such as polycyclic aromatic hydrocarbons 
(PAH, ng/m3) and nitroPAHs (NPAH, ng/m3) (Table 4.2), which 
were measured at the urban and rural sites during different seasons.  
The urban site, which is located in the northern area of the city of 
Bologna, is assumed as representative of the urban background. 
The rural site, which is located in the surrounding of Bologna, in an 
area far from relevant pollution sources, is considered as 
representative of the rural background of the eastern Po Valley. 
In Table 5.5 the results from the chemical characterization of 
samples collected during the different monitoring campaigns were 
reported. The daily mean concentration of pollutants represented 
the human inhalation exposure during the sampling periods at 
different sites, assuming that all the inhaled pollutants reached the 
target tissue. For each sample, the daily concentrations of the 
individual chemicals belonging to the PAH class were summed 
together.  Then, these values were averaged in order to calculate 
the daily mean concentration of the PAH mixture. As the LOD/2 
was assumed to conservatively overestimate the exposure, the daily 
mean concentrations were not representative of the average 
distribution in the different periods, but they were considered as 
representative of the toxicological worst scenario. The sum of the 
daily mean concentrations of PAHs for which a PEF was available 
were also shown in Table 5.5, together with the B(a)P 
concentration, which is commonly considered a marker for 
evaluating the toxicity of PAH mixtures.  
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The micropollutants concentrations in the winter samples were 
always higher than that determined in summer, as expected for 
airborne samples collected in the Po valley area. Moreover, the 
comparison between the urban and rural samples demonstrated that 
the urban samples were significantly enriched in PAHs and B(a)P 
(Student t-test, p<0.01), except for  the IV campaign (winter 2013). 
The B(a)P daily mean concentrations were lower than the 
established EU annual target value (1 ng/m3) in all the sampling 
campaigns (Table 5.8).  
As far as the general trend during the sampling period is concerned, 
it can be observed that the 2011 autumn represents the worst 
scenario, as all the values analyzed (total PAHs, PAHs bearing PEF 
and B(a)P) were higher than all the other campaigns (p<0.01,  
Student t-test) (Graphic 5.5 and 5.6) 
The NPAHs measurements were always near or below the LOD, so 
the daily mean concentrations mainly resulted from the 
implementation of LOD/2, which was used as a precautionary 
measure. As a consequence, the NPAHs concentrations were very 
similar to each other (Table 5.6). The V summer campaign 
represented an exception, as the calculations returned a very low 
NPAHs concentration. The air collection was performed by low 
volume samplers from I to IV campaign, then high volume 
samplers were used. As the LODs were unchanged, the 
concentrations, expressed as ng/m3, lowered as a consequence of 
the sampling procedures. 
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The daily mean concentrations of NPAHs determined at the urban 
site differed from that estimated for the rural site in the III, IV and 
V campaigns (Table 5.6).  
Among the several NPAHs analyzed in this study, 1-nitro pyrene 
and 6-nitrochrysene were the only two compounds for which the 
relative Potency Equivalence Factors PEFs were available (Table 
4.2). So, their concentrations were reported in Table 5.6. 
In Table 5.7 the concentrations (ng/m3) of B(a)P equivalents are 
shown. Even if the NPAH measurements were always near or 
below the LOD, the contribution of NPAHs to the B(a)P equivalent 
calculation was taken into account. The potency for 1-nitropyrene 
is extremely low (PEF = 0.1), while for 6-nitrochrysene the relative 
PEF is 10. So, the NPAHs equivalents were mainly attributable to 
the 6-nitrochrysene B(a)P equivalents transformation (Table 5.7).  
B(a)P equivalents were very similar in the urban and rural sites 
during the same season. Some differences, however, were detected 
during the I and V campaigns (Student t-test, p<0.01and p<0.05 
respectively), even if the leading trend was associated with the 
season of sample collection. 
The contribution to B(a)P equivalents due to PAHs was higher than 
that of NPAHs, except for the 2012 summer campaign, where the 
concentration of PAHs B(a)P equivalents was very low compared 
to the concentration of NPAHs B(a)P equivalents (Table 5.7).
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Table 5.5:   Data are expressed as mean concentration ± SD of total PAHs, PAHs with PEF and B(a)P collected during the monitoring campaigns. 
a Significantly different (p<0.01) from rural site at the Student t-test. 
b Significantly different (p<0.05) from rural site at the Student t-test. 
c Not significantly different  from rural site at the Student  t-test 
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Table 5.6   Data are expressed as mean concentration ± SD of total NPHAs, 1-nitropyrene B(a)P equivalent and 6-nitrochrysene B(a)P equivalent collected during the monitoring 
campaigns. 
 a Significantly different (p<0.01) from rural site at the Student t-test. 
b Significantly different (p<0.05) from rural site at the Student t-test. 
c  Not significantly different from rural site at the Student  t-test 
97 
 
 
Table 5.7:   Data are expressed as mean concentration ± SD of PAH B(a)P equivalent, NPAH B(a)P equivalent and PAH + NPAH B(a)P equivalent collected during the 
monitoring campaigns. 
 a Significantly different (p<0.01) from rural site at the Student t-test. 
b Significantly different (p<0.05) from rural site at the Student t-test. 
c Not significantly different  from rural site at the Student  t-tes
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Graphic 5.5: mean ± SD of total PAHs in six different campaigns 
 
Graphic 5.6: mean ± SD of B(a)P in six different campaigns 
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5.5.2 Cancer risk: PAHs and NPAHs 
In order to calculate the cancer risk, the values derived from the 
transformation of PAHs and NPAHs in B(a)P equivalents were 
used. These values were usually evaluated to obtain the assessment 
of the carcinogenic risk associated with complex mixtures. The 
cancer risk was calculated multiplying the exposure (concentration 
of pollutants in the air expressed as ng/m3) for the cancer risk unit 
(1 x 10-4/ng/m3) determined for B(a)P equivalents (CCTN, 1991; 
WHO, 2000).  
The cancer risk estimates from B(a)P life-time inhalation and from 
PAHs and NPAHs life-time inhalation, expressed as B(a)P eq, are 
shown in Table 5.8 and Table 5.9. 
A comparison between the cancer risk associated with PM 
inhalation at the urban and rural sites during the same season was 
carried out first. Then, the comparison was extended to all the 
different monitoring campaigns. 
The human exposure to polluted air in the summer seasons was not 
associated with an excess of cancer risk. The cancer risk associated 
with chronic inhalation of complex mixtures estimated on B(a)P 
equivalents appears to be about 1 x 10 -5 for the summer campaigns 
and 1 x 10-4 for the autumn-winter campaigns, except for the I 
autumn campaign 2011 (4 x 10-4) and the VI autumn campaign 
2013 (3 x 10-5) (Table 5.9 and Graphic 5.7). 
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Table 5.8: Cancer risk assessment B(a)P  
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Table 5.9: Cancer risk assessment B(a)P equivalents 
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Graphic 5.7: values cancer risk assessment during the different monitoring campaigns 
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CHAPTER 6 
Discussion and conclusions  
6.1 Cell Transformation Assays 
Even if in most areas the air quality has improved substantially 
over the past decades, the air pollution still causes several problems 
that can impact the quality of life and even life expectation of the 
population resident in polluted areas. It has been estimated that the 
cost to society of air pollution in Europe, including damages to 
agriculture and buildings, is about € 23 billion per year.  
While several harmful pollutants, such as sulphur dioxide, lead, 
nitrogen dioxide, carbon monoxide and benzene have decreased 
sensibly as a consequence of the EU air quality policy (EU, 2008), 
fine particulates (PM2.5, PM1) and ozone, in particular, continue to 
present significant health risks.  
PM2.5, measured at the urban background locations in larger cities, 
is considered the best indicator to assess the exposure of general 
population. The average exposure indicator (AEI) is determined as 
a 3-year running annual mean of PM2.5 concentrations and should 
not exceed 20 µg/m3 PM2.5 according to the Clean Air Policy 
Package (EU, 2013). These limits are often exceeded in European 
cities mainly due to road traffic emissions, particularly from diesel 
vehicles (EEA, 2013).  
Po valley is considered one of the most polluted areas in Europe 
due to particular climate conditions and geographical location. The 
average exposure in the area has been calculated to be 21-23 µg/m3  
PM2.5, ranging 14-28 µg/m
3.  
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Modelling the human exposure in in vitro system is always 
challenging. When designing the study, we took into account the 
need of simulating a realistic human exposure, the level of 
concentration that gave an acceptable rate of toxicity. The most 
recent calculation of the recommended Long-Term Exposure 
Values for Inhalation was reported by USA-EPA (Exposure 
Factors Handbook: 2011 Edition). The lowest value was calculated 
for 1-3 months old children (mean 3.5 m3/day, 95th percentile 5.8 
m3/day), the highest value was referred to 16-21 years old adults 
(mean 16.3 m3/day, 95th percentile 24.6 m3/day) (US-EPA, 2011). 
Before then, it was common practice to consider the inhalation 
values ranging from 21 to 23 m3/ day in adults (Snyder et al., 1975; 
US-EPA, 1989) and derive the exposure for infant and children by 
simple extrapolation from these values.  
Based on the available information at the time we planned the 
experiment, 12 m3 represent the highest exposure for residents in 
the Po Valley in 12 h/ day of outside activity. The lowest 
experimental concentration was representative of the infant 
exposure that we calculated as being 0.9 m3/day. This calculation 
was performed as the worst exposure scenario (the most polluted 
site, in the most polluted season). For this reason and to make the 
comparison possible, we use the same volumetric concentration for 
all the samples, even if the amount of PM was different. The 
highest experimental concentration was also the maximum 
tolerated dose, based on the preliminary results on cell clonal 
efficiency. 
The evaluation of the toxicity and carcinogenicity of complex 
mixtures by alternative methods to animal bioassay could help in 
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the prediction of risk linked to carcinogenic compounds present in 
the environmental sample (Colacci et al., 2014). 
The BALB/c 3T3 and Bhas 42 CTAs were used to highlight the 
cytotoxicity and transforming properties of airborne samples 
collected (PM2.5 and PM1) during different seasons at the urban 
site.  
None of the organic and inorganic extracts of PM2.5 and PM1 
induced a significant increase in the average number of 
transformed foci/plate or in the transformation frequency of 
BALB/c 3T3 A31-1-1 cells, except for the organic extract of PM2.5 
collected during the I autumn campaign (2011) (Figure 5.3). 
The results obtained by BALB/c 3T3 cell transformation showed a 
dose-related toxicity for all the organic samples of PM1 and PM2.5, 
whereas the aqueous extracts (PM1 and PM2.5) did not induce any 
cytotoxic effects. The cytotoxicity induced by the samples varies in 
relation to the sampling period, showing seasonal effects (Graphic 
5.1). These effects are probably related to the high levels of PM2.5 
and PM1 (µg/m
3) and to the higher concentration of PAHs in the 
winter-autumn particulate (Graphic 5.2). 
The toxicological effects of airborne particulate have been 
correlated with the total amount of PAHs or modified PAHs 
measured in the extracts or in the sampled air (Colacci et al., 2007; 
De Martinis et al., 1999; Zhao et al., 2003; McDonald et al., 2004; 
Sharma et al., 2007; Kang et al., 2010). Some PAHs and nitro-
PAHs induce transformation in BALB/c 3T3 cells or in Bhas 42 
cells, which originates from the oncogenic transfection of 3T3 cells 
(Asada et al., 2005; OECD, 2007; Sakai et al., 2010).  
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In 2010, IARC revised the classification of PAHs for 
carcinogenicity, taking into account the epidemiological evidence 
and results from bioassay and mechanistic in vitro studies that were 
available at the time (IARC 2010). From studies on binary mixtures 
of PAHs characterized by different carcinogenic potencies, it has 
been hypothesized that PAHs exhibit an additive behaviour at high 
doses, which became more than additive at low and very low doses. 
The effect at higher doses could be due to metabolic saturation 
(IARC 2010).  
It was previously demonstrated that the in vitro cell transformation 
does not depend only on the content of well known carcinogens, 
such as PAHs, but also on other components in the complex 
mixtures (Ohmori et al., 2013). The chemical characterization of 
the PM samples collected in this study showed that the 
concentrations of well known carcinogens, such as several PAHs, 
were generally low.  
Two different campaigns (III autumn 2012 and V summer 2013) 
were evaluated by the Bhas 42 CTA:  
- in the initiation assay the organic extracts of PM2.5 and PM1 
collected during the III autumn campaign 2012 induced a 
significant increase in the average number of transformed foci/plate 
(Figure 5.17) whereas the organic extracts of PM 2.5 and PM 1 
collected during the V campaign (summer 2013) did not show any 
initiating effect (Figure 5.19 );  
- in the promotion assay all the analyzed organic extracts showed 
promoting effect (Figure 5.18 ; Figure 5.20). 
These results apparently did not agree with those obtained in the 
BALB/c 3T3 CTA, where the analyzed PM extracts were not able 
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to enhance cell transformation. The results obtained in the two 
different CTAs (BALB/c 3T3 and Bhas 42) are not easy to 
compare, since the two protocols differ in relevant parameters such 
as cell number at seeding, treatment schedule, the maximum 
concentration of particulate that can be delivered to cells and also 
in term of statistical analysis.  
The different characteristics of the cell lines constitute another 
relevant aspect that should be taken into account in the evaluation 
of the experimental results. The Bhas 42 cell line was established 
by the transfection with a plasmid pBR322 containing the v.Ha-ras 
oncogene into the BALB/c 3T3 A31-1-1 cell line and is presumed 
to be initiated toward transformation by the introduced ras 
sequences (Sasaki et al., 1988; Sasaki et al., 1990). So, the Bhas 42 
cell line is commonly considered to be an initiated cell line having 
progressed to a certain extent along the multi-step carcinogenesis 
process (Bozic, et al., 2010). This means that these cells advanced 
beyond a “normal” condition toward a more atypical pathological 
state. This attribute makes Bhas 42 cells highly sensitive to 
carcinogenic stimuli and accounts for the short latency period of 
expression of the transformed focus phenotype (Sasaki et al., 2015; 
DRAFT Guidance Document, 2015). Actually, the ras gene is a 
major component in the signal transduction pathways  and its 
activation is an important factor in the malignant growth (Zenonos 
et al., 2013).  
The cell transformation assays are considered one of the most 
appropriate approaches to predict the carcinogenic potential of 
chemicals by using alternative in vitro methods. The CTAs have 
been validated for individual chemicals, but could be successfully 
used to analyze complex mixtures and environmental contaminants 
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(Vasseur et al., 2012; Vanparys et al., 2011; Corvi et al., 2012). 
The combined use of both BALB/c 3T3 and Bhas 42 CTA could 
help in enhancing the accuracy of the evaluation of the 
carcinogenic potential, leading to the reduction of the occurrence of 
false negatives.   
Results from a transcriptomics-based study performed by treating 
BALB/c 3T3 with PM2.5 organic extracts supported  the seasonal 
effect on the toxic behavior of PM extracts: Moreover, the analysis 
of the KEGG’s pathways suggested the induction of early events in 
the multistep process leading to cellular transformation and cancer 
(Vaccari et al, 2015). 
The concentration of pollutants in the mixtures and  the time of 
exposure were probably sufficient to highlight toxic effects, but not 
to lead to the growth of fully malignant foci in the 3T3 model. The 
winter extracts, which are characterized by higher concentration of 
pollutants, were able to induce transformation in the more sensitive 
Bhas 42 CTA. 
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6.2 Risk assessment  
The risk estimation of environmental exposures is still a critical 
issue. The composition profile of the environmental mixtures of 
PAHs and NPAHs associated with airborne PM is deeply affected 
by vehicular traffic, antropogenic activities and meteorological 
conditions. The large number of chemicals which are contained in 
PM extracts varies between the source of the sample and the 
sampling seasons. Not all components in the complex mixture may 
be equally identified and characterized. Individual chemicals 
present in the mixture may induce cancer by more than one 
mechanism of action. The mechanisms operate with different dose–
response relationships and interactions between several 
environmental carcinogens co-present in a complex mixture at low 
doses are difficult to predict. All these factors contribute to the 
difficulties in obtaining reliable cancer risk estimates with 
relevance for humans. 
The approach used in this study is based on the WHO 
recommendations for the quantitative assessment of cancer risk by 
inhaled PAHs (WHO/IPCS, 1998). It takes into account the 
micropollutants concentrations which are measured in the 
environmental mixtures and the potency equivalence factors which 
correlate the carcinogenic potential of each PAH or Nitro-PAH 
(NPAH) to that of the reference compound B(a)P. 
As expected for airborne samples collected in the Po valley area, 
the samples collected during winter presented micropollutants 
concentrations higher than that determined in summer. Moreover, 
the amounts of PAHs were significantly higher in the urban 
samples.  
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In the directive 2004/107/EC (Fourth Daughter Directive), the EU  
set a target value for polycyclic aromatic hydrocarbons (PAH) for 
the protection of human health. The target is defined in terms of 
concentration of benzo(a)pyrene (BaP) which is used as a marker 
substance for PAHs. The B(a)P annual mean value may not exceed 
1 nanogram per cubic metre (ng/m3). The B(a)P concentrations 
measured in summer (2012 and 2013) and autumn 2013 are 2 
orders of magnitude lower than to the target value . None of the 
daily mean concentrations of B(a)P measured during the project 
exceeded the limit value (Table 5.5).  
The application of the UR cancer risk to the transformed value of 
B(a)P equivalents in the winter–autumn campaigns leads to 
estimate an increase in the cancer risk similar to that defined in the 
literature (1 x 10-4 for exposure to 1 ng/m3) (WHO 2000; CCNT, 
1991).  The calculated cancer risk was about one order of 
magnitude lower in the summer campaigns (Table 5.9). 
The prediction of excess of deaths for cancer diseases due to the 
inhalation exposure did not raise specific concern and strengthened 
the results obtained in the investigation carried out with biological 
approaches.  
In conclusion, the proposed approach, based on the integration of 
the data derived from in vitro testing and cancer risk assessment, 
could represent a reliable model for investigating environmental 
mixtures and predicting their effects on toxicological relevant 
endpoints. 
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